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Executive summary 
Over the past 50 years, several jurisdictions in Europe, Australia and the Americas have reduced the 
penalties associated with using or possessing small amounts of cannabis. As of December 2019, 
Canada, Uruguay and 10 US states have gone further and passed laws that license the production 
and retail sale of cannabis, mostly by private companies, to adults for non-medical — sometimes 
referred to as recreational — purposes (1). With discussions about alternatives to cannabis 
prohibition becoming more common in some parts of the world, there is a growing interest in learning 
from the cannabis policy changes in the Americas. 
To learn more about these new cannabis regimes and their consequences, the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) commissioned a review of the changes governing 
recreational cannabis policies in the Americas and an overview of preliminary evaluations. Findings 
from this research are intended to inform discussions about the development of a framework for 
monitoring and evaluating policy developments related to cannabis regulatory reform. Key insights 
include the following. 
 In addition to the populations of Canada and Uruguay, more than 25 % of the US population
lives in states that have passed laws to legalise and regulate cannabis production, sales and
possession/use for recreational purposes. In the US, allowing licensed production and sales
is often at the discretion of sub-state jurisdictions, which may impose further zoning
restrictions on cannabis-related activities. This variation can complicate analyses that attempt
to compare legalisation and non-legalisation states, especially when the outcome data are not
representative at state level.
 The peer-reviewed literature on cannabis legalisation is nascent, and we observe conflicting
results depending on which data and methods are used, as well as which implementation
dates and policies are considered. It is important to remain sceptical of early studies,
especially those that use a simple binary variable to classify legalisation and non-legalisation
states. This scepticism should extend to the many studies that fail to account for the existence
of robust commercial medical cannabis markets that predate non-medical recreational
cannabis laws. Even if a consensus develops on certain outcomes, it does not mean that a
relationship will hold over time. Changes in the norms about cannabis use and potentially
other substances, the maturation of markets and the power of private businesses (if allowed)
could lead to very different outcomes 15 or 25 years after recreational cannabis laws have
passed. Evaluations of these changes must be considered an ongoing exercise, not
something that should happen in the short term.
 One area in which there seems to be a consensus — so far — is with respect to cannabis-
involved hospitalisations and emergency department (ED) visits in Colorado. While studies
have observed increases in the number of adverse events after changes in medical or
recreational supply, they tend to utilise a simple pre-post design without a control group.
Thus, they do not produce causal estimates, and it is possible that some increases could be
due to changes in reporting or measurement. For example, it is unclear if increases in the
number of ED visits and hospitalisations are due to a greater willingness on the part of
individuals to report the use of cannabis and/or if doctors are more aware of acute cannabis
intoxication after the policy change and are now more likely to screen or confirm with
urinalysis.
 One insight arising from the evaluations of the regulatory changes in the Americas to date is
the importance of the amount and range of data collected before the change; simply
(1) Two other US jurisdictions, the state of Vermont and the District of Columbia, also allow the cultivation and possession of
cannabis for adults but do not permit its commercialization.
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comparing past-month prevalence rates will not tell us much about the effect of the change on 
health. While US jurisdictions have been moving quickly to legalise the use of cannabis, the 
data infrastructure for evaluating these changes is limited. In contrast, Canada has made 
important efforts to field new surveys and create new data collection programmes in 
anticipation of legal changes. This highlights the importance of any jurisdictions that are 
considering changes to the regulatory framework for cannabis starting to think about 
improving data collection and analysis systems in advance. 
 While there is much to learn from what is happening in the Americas, policy discussions
should not be limited to approaches that have been implemented there. There are several
regulatory tools (e.g. minimum pricing, potency-based taxes) that receive very little attention
— if any — that could have important consequences for health, public safety and/or social
equity. It needs to be recognised that all decisions of this nature involve trade-offs and
acknowledging that individuals (and governments) have different values and preferences for
risk when it comes to cannabis policy is important for productive debates on this controversial
topic.
6 
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Foreword 
The EMCDDA exists to facilitate an evidence-informed understanding of issues that are important for 
developing better drug-related policies and actions across Europe. In our series of reports, Cannabis: 
controversies and challenges, we focus attention on an illicit drug with a long history of use that has 
recently been an area of rapid policy development and intense European and wider international 
drug policy debate. In some countries, questions on what constitutes an appropriate policy response 
to cannabis have become both more topical and important. The aim of this set of publications is to 
explore, in an objective and neutral manner, some of the complex issues that exist in this fast-
changing area. 
The paper Medical use of cannabis and cannabinoids: questions and answers for policymaking, 
published in December 2018, provided an overview of developments in the way in which countries 
and jurisdictions are regulating the use of cannabis and cannabinoids for medical purposes. In this 
report, the latest in the series, the focus is shifted to recent changes to regulatory systems in the 
Americas that permit the consumption of cannabis by adults for non-medical, recreational purposes. 
In order to improve our understanding of these new cannabis regimes and their consequences, the 
EMCDDA commissioned RAND Europe and the RAND Drug Policy Research Center to undertake a 
review of the changes to recreational cannabis policies in the Americas and produce an overview of 
the evidence emerging from preliminary evaluations.  
At this stage the evidence base is still insufficient to comment with any certainty on the impact of the 
changes that are occurring in the Americas. However, this is a rapidly developing area and this 
review provides a detailed summary of the current evidence base. The EMCDDA will continue to 
follow up on developments to help inform the European debate in this area.  
Importantly, this review, in addition to providing EU audiences with a clearer picture of the 
developments occurring in the Americas, also highlights some of the challenges associated with 
monitoring and evaluating regulatory changes in the drugs field. We trust that this report will be of 
particular use to those involved in planning or evaluating any changes to cannabis regulation.  
Alexis Goosdeel 
Director, EMCDDA 
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1. Introduction
The cannabis policy landscape in the Americas is dramatically changing. Individual states in the US 
began liberalising their cannabis laws as far back as the 1970s, when several of them reduced or 
removed criminal penalties for possession of small amounts of cannabis. Starting in the 1990s, US 
states began to allow individuals to possess cannabis for qualified medical conditions. In contrast to 
subsequent European systems, medical cannabis in the US was primarily voter initiated and allowed 
people to grow and smoke non-standardised cannabis herb for a wide range of medical indications. 
These early medical cannabis reforms maintained state-level prohibition, except for a class of patients 
who obtained recommendations from authorised medical practitioners. 
Distinct from, and in marked contrast to, these earlier medical cannabis reforms, voters in the US 
states of Colorado and Washington passed ballot initiatives in 2012 to repeal the prohibition on adult, 
non-medical cannabis and to license for-profit firms to produce and sell the drug to adults aged 21 
years and over. Since the 2012 election, 10 more US jurisdictions have approved commercial models 
for non-medical cannabis, and in two others (Vermont and the District of Columbia — DC) non-
commercial approaches have been adopted. 
However, reforms to cannabis supply laws in the Americas are not limited to the US. In late 2013, 
Uruguay became the first country in the world to repeal prohibition on cannabis supply for non-
medical markets; however, its approach is more restrictive than the regulated commercial regimes 
adopted in the US. Registered adults in that country could begin growing a small number of plants at 
home or join a social club in late 2014; by mid-2017, individuals could buy rationed amounts of 
cannabis, grown by state-authorised producers, in licensed pharmacies that chose to sell it. In June 
2018, Canada became the second country to legalise cannabis production and supply for non-
medical purposes; retail stores opened in some provinces, starting in October 2018. In addition, other 
countries in the Americas have passed laws to permit access to cannabis or cannabis-derived 
products for medical purposes. 
Apart from the regulatory changes in the Americas, which are the focus of this report, changes are 
occurring globally. For example, the Dutch government is implementing its 2017 commitment to 
experiment with a closed supply chain to coffee shops, while Malta’s government has taken steps to 
launch a national debate on whether or not there could be recreational cannabis use, and how this 
should be implemented. In 2018, the parties forming the government of Luxembourg reached an 
agreement that may allow for the future sale of cannabis to residents, while the highest courts in 
South Africa and Georgia have initiated reforms based on human rights that permit the consumption 
of cannabis in private settings, but not its sale. Other countries have not formally legalised cannabis 
but may have reduced the emphasis that they place on control or introduced some formal or informal 
tolerance for personal use of the drug. 
The focus of this report is on changes that are relevant to recreational cannabis, sometimes referred 
to as adult or non-medical cannabis, with an emphasis on the implementation of commercial models 
in US states. The report does not separately evaluate medical cannabis reforms in the US or 
elsewhere. These are discussed only insofar as they help to explain the context in which subsequent 
recreational cannabis reforms took place. Cannabis and cannabinoids are made available for medical 
use in a wide variety of ways; hence the term ‘medical cannabis’ can be used to describe many 
different products and forms of supply. For reviews of the evidence on the various medical regimes, 
see Pacula and Smart (2017), the EMCDDA (2018) report Medical use of cannabis and cannabinoids 
— questions and answers for policymaking and the accompanying summary of reviews (Hall, 2018). 
Similarly, this report does not examine reforms aimed at reducing criminal penalties for possession or 
use but focuses on the broader set of policy changes aimed at regulating the recreational cannabis 
market. 
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To learn more about these new cannabis regimes and their consequences, the EMCDDA 
commissioned a review of changes governing recreational cannabis policies in the Americas and an 
overview of preliminary evaluations. Findings from this research are intended to facilitate a better 
understanding among the EU audience of developments occurring in the Americas and to inform 
discussions about the framework necessary for monitoring and evaluating policy developments 
related to cannabis policy changes that might increase the availability of this substance within Europe. 
This report is structured as follows: following this introduction, Section 2 provides the background to 
and context of recent developments in cannabis policies in the Americas, with a particular focus on 
the more mature state commercial markets in the US; Section 3 offers a description and typology of 
different policy approaches with supporting case summaries; Section 4 presents an assessment of 
early evidence of the impact of policy changes in this area; and Section 5 provides guidance for 
European policymakers considering regulatory changes in the cannabis area on the establishment of 
a comprehensive, monitoring and evaluation framework. Appendix A highlights some of the ongoing 
and planned studies of legalisation implementation and its consequences in the Americas. 
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2. Background to cannabis policy developments in the Americas 
Changes in cannabis policy that introduce greater tolerance can take various forms. Countries in 
Europe and elsewhere have reduced penalties for low-level offences, have removed criminal 
sanctions for possession or use or have introduced formal or informal procedures that reduce the 
likelihood of sanctions being applied for some forms of personal possession or use. However, up to 
now these policy changes have taken place within the overall context of maintaining the prohibition of 
cannabis supply and not establishing a regulated market for the drug for recreational users. This is an 
important distinction, because efforts to repeal prohibition and replace it with rules governing 
production, distribution and possession/use of cannabis are expected to have a greater impact on 
public health and safety than amending laws related to possession or use. However, many 
jurisdictions in the Americas have begun to repeal the prohibition of cannabis, allowing licensed 
businesses to produce and supply it for a narrow set of qualified medical patients (i.e. medical 
cannabis) or any adult over a minimum age (i.e. recreational cannabis). The main focus of this report 
is on recent efforts aimed at replacing cannabis prohibition with regulated regimes that permit 
recreational cannabis. However, some information relating to medical cannabis regimes is also 
provided, as they have been a very common step in the evolution of cannabis regulatory 
developments in the Americas (Kilmer and MacCoun, 2017) and are therefore relevant to 
understanding the context of subsequent reforms in relation to recreational cannabis use. 
The move towards changing cannabis laws to allow medical access is driven by multiple factors. 
Three common arguments are (1) the desire to improve the lives of patients who could immediately 
benefit from these products, particularly when they are produced in a manner that can ensure 
consistency and quality; (2) the desire to learn more about the medical benefits and risks of these 
products; and (3) the desire to take action to soften prohibition and improve civil liberties. Another 
driver of change that is becoming increasingly important in some jurisdictions is the desire to generate 
legal economic activity and tax revenues from cannabis businesses (Subritzky et al., 2016; Hall and 
Kozlowski, 2018). 
It is also important to consider these medical laws when thinking about the move towards legalising 
recreational cannabis. As Table 2.1 makes clear, only a small minority of countries that allow medical 
cannabis have made the move towards permitting adults to access cannabis for recreational 
purposes. In contrast, Uruguay did not start developing a medical programme until after legislation for 
recreational cannabis was passed. This legislation was pushed by the government largely to reduce 
drug-related crime and violence associated with the cannabis trade (Aguiar and Musto, 2015). 
Despite its initial unpopularity with the citizens of Uruguay (Garat, 2015), it was signed into law in 
December 2013. 
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TABLE 2.1 
Changes to cannabis supply laws in the Americas 
Country  Implemented 
nationally 
Year 
passed 
Comments 
Medical 
United States  No  1996 
onwards* 
In total, 33 states and DC have passed laws to allow cannabis flowers and other 
products to be produced and distributed for qualifying conditions. Thirteen other states 
allow physicians to recommend or individuals to obtain CBD oils, but do not necessarily 
permit their production. This all remains illegal under federal law. 
Canada  Yes  2001  Currently, all medical cannabis is supposed to be produced by federally licensed private 
companies and delivered by post. Efforts are being made to eliminate the illegal 
dispensaries that still operate in some jurisdictions. Registered patients may also 
cultivate a limited amount at home for their own personal needs. 
Uruguay  Yes  2013  Production is licensed by state, and extracts are available in pharmacies for those with a 
physician’s prescription. Currently products containing CBD and a low THC 
concentration are available for a set of conditions. 
Chile Yes 2015 There is limited access to cannabis-derived products approved by health authorities, 
which currently include only imported high-CBD/low-THC oils available in pharmacies. 
There is an ongoing pilot project with one domestic cultivator. 
Jamaica  Yes  2015  Licences have been granted since 2017. As at mid-2018, there are a handful of 
cultivators and processors as well as two medical dispensaries. Regulations allow small- 
and large-scale production of medical cannabis for residents as well as tourist and export 
markets. 
Colombia  Yes  2015  The decree signed in December 2015 permits medical cannabis under the national drug 
law. The decree was superseded by law. The Ministry of Health has licensed cultivators, 
although it is unclear how much cannabis production will be permitted. The law and 
accompanying regulations focus on export markets. 
Brazil Yes 2016 The health agency resolution allows the importation of cannabis oils for epilepsy and 
multiple sclerosis. 
Argentina Yes 2017 A law and a ministerial decree have directed the Ministry of Health to draft regulatory 
guidelines to allow the state to produce and patients to inscribe into a programme to 
obtain or import cannabis oils and other derivatives for treatment of qualifying conditions. 
Mexico Yes 2017 A legislative act and regulatory decree were passed in 2017 to permit the importation of 
medicinal products to treat qualifying conditions. Regulations have not yet been finalised. 
Peru Yes 2017 A law was passed to guide the Ministry of Health with regard to drafting appropriate 
regulations to allow doctors to prescribe and patients to obtain cannabis and cannabis 
derivatives. 
Recreational** 
United States  No  2012*  Ten states have passed laws to allow for-profit companies to produce and sell cannabis 
(Alaska, California, Colorado, Illinois, Massachusetts, Maine, Michigan, Nevada, Oregon 
and Washington) to anyone aged 21 years and over; DC and Vermont allow only home 
production and sharing of cannabis. Production and possession remain illegal under 
federal law. 
Uruguay  Yes  2013  Residents aged 18 years and over must register with the government to either grow 
cannabis at home, join a collective or purchase cannabis from pharmacies. Home 
growing of cannabis and social clubs started operating in the latter half of 2014. State-
licensed companies produce retail products sold in pharmacies. Sales began in mid-
2017. The government determines the price and potency of cannabis sold in 
pharmacies. Pharmacy sales have slowly been introduced, partly because of issues 
pertaining to the access of financial institutions with branch offices in the US. 
Canada Yes 2018 In mid-2018, the Canadian parliament passed the Cannabis Act to permit adults to 
cultivate, process and use cannabis for recreational purposes. The law came into effect 
in October 2018. Under the law, the provinces are given regulatory power with regard to 
distribution, but federal law provides general rules on production, promotion, packaging 
and licensing. 
* Federal law still prohibits cannabis. The date reflects the date when the first state passed a law. 
** In October 2018, the Mexican Supreme Court ruled that prohibiting cannabis for personal use is unconstitutional; however, this does 
not technically legalise use and supply. The legislature is working to amend the law, to codify the ruling. For more information, see Lopez 
(2018).  
THC, tetrahydrocannabinol — the principal intoxicative agent in cannabis; CBD, cannabidiol — a cannabinoid that has the potential to 
reduce certain maladies and attenuate some of the effects of THC. 
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Most of the changes have been limited to supplying cannabis for medicinal purposes, and there is an 
important variation in what these legal frameworks allow. These regulatory systems and the products 
that are available to patients differ from traditional medicinal formulations that contain synthetic 
cannabinoids (e.g. dronabinol or nabilone) or plant-derived preparations approved by the government 
(e.g. Sativex or Epidiolex). Some jurisdictions make it easy for patients to access a myriad of 
cannabis preparations, including raw or herbal products that can be smoked or vaporised (e.g. many 
US states, Canada), as well as various cannabis-derived preparations, such as vaporisable 
concentrates, tinctures, edibles and topicals. More restrictive markets only allow cannabis extracts 
with high levels of cannabidiol (CBD) and a trace or modest amounts of tetrahydrocannabinol (THC) 
(e.g. about a dozen US states, Chile, Brazil, Mexico) or limit the types or forms of cannabis available 
to patients (e.g. prohibiting smoking of herbal or raw cannabis). 
However, in US states, recreational legalisation has followed the provision of medical cannabis, and 
multiple hypotheses have been offered about how the latter may have smoothed the transition to the 
former. Kilmer and MacCoun (2017) offer five potential explanations for the transition: 
(a) it demonstrated the efficacy of using voter initiatives to change cannabis supply laws; 
(b) it enabled the psychological changes needed to destabilise the ‘war on drugs’ policy stasis; 
(c) it generated an evidence base that could be used to downplay concerns about non-medical 
legalisation; 
(d) it created a visible and active cannabis industry; 
(e) it revealed that the federal government would allow state and local jurisdictions to generate 
tax revenue from cannabis. 
Of course, some of these reasons are specific to the US (e.g. state ballot initiatives and federalism). 
With respect to the visibility of the cannabis industry, Kilmer and MacCoun (2017) note the following: 
The proliferation of medical dispensaries in the 2000s introduced the public to the idea of 
stand-alone stores selling [cannabis] products (and not just to those residing in states that 
allow medicinal [cannabis], as dispensaries are regularly featured in media stories across the 
country). Subsequent advertisements in alternative weekly newspapers and occasionally on 
billboards also exposed voters to this new quasi-legal industry. 
Of course, not everyone is thrilled with the establishment of medical dispensaries and the 
related advertising, and there is tremendous variation in what states allow and how they are 
regulated (Pacula et al. 2015). Further, even in states that allow dispensaries, some local 
jurisdictions have decided to prohibit them. But for those who see these dispensaries on a 
regular basis, they not only have a sense of what legalisation may look like but also may be 
desensitised to the idea of retail [cannabis]. In fact, some may conclude that allowing any 
adult to enter those stores instead of only those who have recommendations — which in 
some states are very easy to obtain (e.g., High Times 2016) — may not be a big change. 
Medical [cannabis] laws also created an industry looking to expand its market beyond medical 
patients. Indeed, it is hard to imagine that some of those developing, e.g., brands, new 
methods of ingestion, and improved production methods did not have their sights on a larger 
market. Although those in the advocacy community criticised the industry for not donating 
more to the campaigns (e.g., see quotes from Ethan Nadelmann in Freedlander 2016), some 
with a financial interest did make contributions. 
In Canada, a series of provincial and Supreme Court cases during the early 2000s gradually legalised 
the medical use of cannabis. The initial medical system developed at the national level slowly 
unfolded. In 2001, Canada enacted enabling legislation via the Controlled Drug and Substances Act 
to pass the Marihuana Medical Access Regulations (MMAR). This new set of regulations permitted 
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individuals with qualifying illnesses (which were listed by the regulation) to obtain medical cannabis. 
The initial programme was overly restrictive, so  that many patients wishing to take cannabis for their 
condition had to source it from the illicit market (Fischer et al., 2015). Individuals were allowed to 
obtain cannabis by three different means: (1) by applying to access Health Canada’s supply of dried 
cannabis via the postal system; (2) by applying for a personal-use production licence (i.e. to grow 
cannabis at home); or (3) by designating someone to cultivate on their behalf with a ‘designated-
person production licence’. This last provision was criticised for permitting unregulated and outright 
illicit sales (Fischer et al., 2015). 
In response to concerns from law enforcement and other policymakers that the system governed by 
the MMAR was open to abuse, and after extensive consultations, the Harper government introduced 
the Marihuana for Medical Purposes Regulations (MMPR) in 2013 to further restrict and regulate the 
market by eliminating home-growing of cannabis and limiting designee production. Under the MMPR, 
only licensed producers could cultivate medical cannabis. Justin Trudeau became prime minister in 
2015 and prioritised cannabis policy reform, including the legalisation of recreational cannabis. In 
2016, the MMPR was struck down on constitutional grounds and was later superseded by the Access 
to Cannabis for Medical Purposes Regulations (ACMPR), which built on the existing framework for 
licensed commercial producers established under prior regulations while permitting patients to register 
to cultivate a small amount for personal medical use. Existing producers licensed under the ACMPR 
would later be deemed as such under the Cannabis Act. 
While bricks and mortar medical dispensaries (2) were technically illegal under Canadian law, some 
jurisdictions allowed them to operate; other jurisdictions, such as Vancouver, eventually established 
some licensing and regulatory frameworks to control the growing retail industry (Johnson, 2015). As in 
multiple US states, this probably introduced some Canadians to the idea of stand-alone stores selling 
cannabis products as well as advertising such products. Many Canadian medical cannabis producers 
anticipated supplying the much larger recreational market. As cannabis is federally legal in Canada, 
some of these Canadian firms are listed on major US stock exchanges, in contrast to firms from the 
US, and some investors believe that they are ‘poised to surge’ (Chang, 2018). Yet projections of 
earnings and market valuation have been revised downwards, as sales have not met analyst 
expectations (Subramaniam, 2019). 
Another important difference between Canada and most of the US states that have legalised 
recreational cannabis is the amount of public discussion and deliberation that took place before the 
policy change (3). After Prime Minister Trudeau announced his party’s intentions to legalise cannabis, 
the Liberal government convened a task force that would spend nearly a year collecting information 
about regulating cannabis from several sources, ranging from international experts to domestic 
cannabis users. The task force’s resulting report was released in December 2016. The report and 
subsequent recommendations helped shape the legislation introduced in April 2017. Soon after, there 
were several hearings in parliament about the bill. In the Senate’s Standing Committee on Social 
Affairs, Science and Technology alone, there were 18 hearings. After more than 1 year of 
deliberation, the final bill received Royal Assent in June 2018, and legal sales began on 17 October 
2018. 
                                                     
(2) Shops with a physical location, as opposed to online or virtual businesses. 
(3) The most obvious exception is Vermont. Since 2014, the state legislature has seriously deliberated various legalisation 
proposals, from commercial models to the grow-at-home model, the latter being implemented in 2018. Other state authorities 
have commissioned expert reports assessing the impacts of legalisation (e.g. California) (Caulkins et al., 2015; Newsom et al., 
2015). 
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3. A description and typology of different policy approaches 
Jurisdictions considering alternatives to prohibition on cannabis supply are faced with a wide range of 
options from which to choose. Figure 3.1 presents some alternatives to the status quo prohibition of 
cannabis supply, including eight ‘middle-ground’ options between traditional prohibition and the 
standard for-profit commercial model, which is being adopted in an increasing number of US states. 
However, as will be made clear in this section, the for-profit option is not the only option that is 
pursued in the US, and both Uruguay and Canada have created regulatory regimes intended to limit 
the power of businesses. 
It is also the case that these options are not mutually exclusive. Jurisdictions can allow both home 
production and commercial sales, a scenario that has occurred in most places that have legalised 
cannabis. Furthermore, the choices need not be the same at the various levels of cannabis markets 
(Wilkins, 2016). For example, it is possible to allow commercial businesses to produce cannabis but 
require that its distribution occurs via state-run retail stores, as is the case with alcohol in some 
jurisdictions, or via postal delivery, as is done in some parts of Canada. 
 
 
FIGURE 3.1 
Some alternatives to status quo cannabis supply prohibition 
 
Source: Caulkins et al., 2015 
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3.1 US approaches 
More than 25 % of the US population lives in 10 states where voters have passed laws permitting the 
commercialisation of cannabis production and distribution. Table 3.1 reports dates of passage for both 
medical and recreational legalisation as well as when retail dispensaries began selling recreational 
cannabis to adults.  
While the commercial models in Colorado, Washington and California receive a great deal of 
attention, not all US states that have legalised cannabis have allowed commercial sales. Both DC and 
Vermont have opted for non-commercial access, allowing adults to privately grow and give away up to 
an ounce (28 g) of cannabis. In 2014, DC voters approved Initiative 71, which permits adults to grow 
up to six plants and to give away cannabis without remuneration (4). The law maintains a prohibition 
on selling cannabis and made public consumption a minor offence. The initiative has not been 
formally evaluated, but early media reports suggest that the new law has spurred unregulated 
transactions under the guise of giving cannabis to someone as a gift (Garcia, 2017). 
In addition to DC, the state of Vermont legalised recreational cannabis in January 2018, which came 
into effect on 1 July of the same year. After more than two years of legislative deliberation and a 
government-sponsored report on the options and issues regarding legalisation, Vermont became the 
first state to repeal cannabis prohibition through legislation, rather than an initiative approved by 
voters. Similar to DC, Vermont’s law permits adults aged over 21 years to grow six plants (up to two in 
flower) and to possess or give away up to an ounce of herbal cannabis. It does not permit sales. As in 
the case of DC, ‘grey market’ sales of cannabis, though technically illegal, may be occurring in 
Vermont’s unregulated non-commercial system (Goldstein, 2018). 
TABLE 3.1 
Passage of recreational and medical cannabis laws in US states that permit these 
State 
Medical cannabis law 
passed* 
Recreational cannabis 
law passed 
Start of recreational 
sales 
Alaska 1999 4 November 2014 29 October 2016 
California 1996 8 November 2016 1 January 2018 
Colorado 2000 6 November 2012 1 January 2014 
DC 2010 4 November 2014 Not applicable 
Illinois 2013 25 June 25 2019 Not yet open 
Maine 2002 8 November 2016 Not yet open 
Massachusetts 2013 8 November 2016 20 November 2018 
Michigan 2008 6 November 2018 2 December, 2019 
Nevada 2000 8 November, 2016 1 July 2017 
Oregon 1998 4 November 2014 1 October 2015 
Vermont 2004 22 January 2018 Not applicable 
Washington 1998 6 November 2012 8 July 2014 
*Medical cannabis laws have varied over the years. Here, we report the first year in which the state adopted a 
medical cannabis law, not necessarily when voters approved the initiative. Initially, these laws permitted 
qualifying individuals to possess cannabis. Over time, dispensaries and collective cultivation sites sprung up to 
supply growing patient demand. Since their inception, states have adopted various regulatory approaches, 
formalising commercial medical markets. 
Source: National Conference of State Legislatures (2019) 
                                                     
(4) Many but not all jurisdictions in the US allow citizens to propose initiatives for consideration by voters provided they obtain 
enough signatures.  
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3.2 Uruguay 
In 2013, Uruguay became the first country in the modern era to legalise recreational cannabis use. 
Under the law, resident adults aged over 18 years can register with the state regulatory authority to 
access cannabis through one of three available supply channels. Registrants can switch from one 
supply channel to another, after changing their status with the regulatory authorities. Regardless of 
which supply stream users opt into, they are technically limited to 480 g per year. The three types of 
access are home cultivation, membership at a cannabis social club or retail sale via licensed 
pharmacies. 
Individuals who decide to grow cannabis at home cannot cultivate more than six plants. As of May 
2019, there were some 7 000 registered home growers. Clubs are limited to 45 members and can 
cultivate only up to 99 plants. Currently, there are 119 clubs in operation across the country, servicing 
about 3 600 members. Registered members are prohibited from obtaining more than their allowance 
of 480 g. Those opting to purchase at pharmacies must also register with authorities and are limited to 
purchasing no more than 10 g per week, with an annual cap of 480 g. There are just a few varieties of 
the plant on offer at pharmacies (i.e. regulators currently limit retail pharmacy sales to only a few 
strains), and authorities have aimed to keep potency below 10 % THC. According to regulators, there 
are currently 17 licensed pharmacies, mostly in the capital region, that sell cannabis to about 36 000 
registered adults (5). There are no taxes on retail sales, but the government has set a price of UYU 40 
(about EUR 1) per gram. 
3.3 Canada 
As a federal system, the new recreational cannabis law removes most prohibitions on cannabis from 
national drug control statutes (criminal prohibition on supply to or possession by minors or 
unregulated production remains). In most provinces, adults aged over 18 years can possess up to 
30 g of herbal cannabis (or its equivalent in weight in other forms, such as concentrates (6)). The law 
allows the cultivation, distribution and possession of cannabis by government-authorised entities. 
Federal law provides standards and a general framework for regulating cannabis, including 
requirements for an inventory tracking system, fees, quality and testing rules, restrictions on labelling 
and packaging, prohibitions on promotions aimed at enticing young people and bans on the types of 
products for sale. Federally licensed producers can be publicly traded, for-profit businesses, and 
there are no restrictions on alcohol and tobacco companies receiving a production licence. 
Though the federal government has lifted prohibition, provinces have considerable power in designing 
rules governing distribution, taxation, and establishing age limits for purchase (some provinces opted 
to increase the minimum age to 19 years). Provinces are also tasked with enforcing their own 
regulations. Though federal law permits adults to cultivate up to four plants at home, some provinces 
have banned home cultivation. Provincial retail systems are still evolving, with some opting for public 
distribution channels similar to government-run alcohol stores. 
What distinguishes Canada from the US states that have legalised cannabis is that the federal 
government led the effort to repeal prohibition, with the aim of reducing youth access, protecting 
public health and improving public safety by shrinking the illicit market. Unlike states in the US, 
Canadian provinces do not maintain their own competing criminal drug laws. Another important 
variation found in Canada’s law is that it allows for mail order supply of cannabis, minimising the need 
for bricks and mortar stores. The federal government is also committed to public health and education 
campaigns aimed at reducing problematic use, including underage use. 
(5) See https://www.ircca.gub.uy/farmaciasadheridas/
(6) Under Canadian law, 0.25 g of concentrates is equivalent to 1 g of dried herbal cannabis, and 15 g of solids containing
cannabis is equivalent to 1 g of dried herbal cannabis.
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4. An assessment of early evidence of the impact of policy 
changes in the United States 
This section summarises the early evidence of the consequences of policy changes concerning 
recreational cannabis laws in the US. Here, we focus on the commercial cases that are specific to the 
US, given that these policy changes have unfolded over longer time periods, allowing for more 
evaluations of their impacts. They are also likely to have larger social impacts than non-commercial 
reforms such as home cultivation. Recreational cannabis laws are frequently referred to as 
‘recreational marijuana laws’ and ‘medical marijuana laws’, as in US statutes and regulations 
cannabis is more commonly referred to as ‘marijuana’. We refer to these as REC (recreational) or 
MED (medical) cannabis. Colorado and Washington were the first states in the US to pass REC laws, 
followed by Oregon and Alaska. Though other states, such as Maine and Illinois, have passed similar 
laws, they have yet to fully implement market regulations, or too little time has passed since they have 
been in place to allow the evaluation of the impacts. This analysis largely focuses on the pioneering 
states of Colorado and Washington, where more time has passed and more data have been 
collected. 
Though REC laws have existed only in the last seven years, their adoption follows the passage of 
MED laws and, in some cases, robust commercial markets (see discussion in Section 2). The 
variation in MED laws and associated outcomes has been documented in scientific literature (Cerdá 
et al., 2012; Hasin et al., 2015; Pacula et al., 2015; Hall, 2018); as a result, we do not assess MED 
laws or their policy impacts here. 
The consequences of the REC legal changes analysed here are likely to vary depending on the 
design and implementation of pre-existing medical cannabis laws and the size and scope of state 
commercial markets. For example, jurisdictions with commercial medical markets, lax restrictions on 
patient access and minimal regulatory burdens may not observe as many post-REC changes as 
states that restricted medical access to a narrow set of qualifying conditions or limited the number of 
dispensaries (7). In some cases, the adoption of REC laws is a marginal change (Colorado and 
California had large, loosely regulated medical markets for more than a decade before the adoption of 
REC laws, and the regulation of medical markets in Washington state did not occur until after the 
passage of REC laws); for other states, recreational laws are more novel (Massachusetts and Maine 
have had smaller or limited commercial medical markets for shorter time periods). 
An assessment of the adoption of REC laws (and MED laws before them) must consider the 
underlying economic and social trends. Legalisation — but more importantly commercialisation — is 
likely to affect social norms by promoting use, normalising behaviours, increasing availability, 
introducing new products and lowering price (Caulkins et al., 2015; Hall and Lynskey, 2016; Subritzky 
et al., 2016; D’Amico et al., 2018). The extent to which any or all of these consequences resulted in a 
net benefit or net cost to society is unclear. Nevertheless, many consequences may depend on the 
timing of REC legalisation and its implementation and the shape in which both unfolded. Therefore, 
examining changes in commercial access (e.g. when stores opened) is perhaps a more accurate 
exposure variable than the date when a law was adopted. In addition to timing, an ideal measure for 
REC exposure should account for retail store density, something most of the literature has omitted in 
its analysis. 
                                                     
(7) As the US federal government maintains the scheduling of cannabis as a Schedule I drug and because pharmacies require 
a federal licence to distribute controlled substances for medical purposes, medical cannabis products cannot be distributed 
through traditional pharmacies, even in states that permit cannabis for medicinal use. This is, in part, how and why the 
cannabis dispensary system started in the US. 
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4.1 Literature review selection criteria 
We reiterate that the contemporary literature base on REC law impacts is thin, given that policies are 
still developing, markets are still maturing, and there are significant data gaps. Furthermore, states 
are adopting these legal changes against a backdrop of federal prohibition. Therefore, the full extent 
of these effects may change considerably in an environment in which the substance is legal at the 
national level (e.g. in Canada or Uruguay). Interstate trade and federal tax policy could have broad 
implications on the outcomes assessed here. Looking to the future, the immediate outcomes 
evaluated in this review may not reflect long-term outcomes, which may take decades or longer to 
develop. We therefore urge caution when interpreting the short-term measures and findings reported 
below. 
That said, we assessed the emerging evidence on the outcomes of REC law changes. We excluded 
studies specific to MED, though the context of REC adoption and design is relative to a state’s 
medical framework. These underlying legal and social factors related to MED may extend to 
differences in the outcomes reported post REC adoption. We also note that many studies specify 
various policy interventions, sometimes unclearly. Several peer-reviewed articles focus on REC 
enactment (after a law was passed to effect a change; in most cases, the prohibition on possession or 
home cultivation was lifted before implementation) or REC implementation (once the law is in effect 
and retail stores are open). Some ignore the distinction entirely, blending the two, rather than 
evaluating impacts in policy change after enactment or implementation. 
We prioritise peer-reviewed articles over the grey literature or reports published by advocacy groups, 
but we have included a few well-designed working papers. In terms of the research design of articles, 
we highlight findings from quasi-experimental studies that include a control group or employ an 
interrupted time series method to assess policy impact (8). Studies that use state representative 
samples are prioritised over studies that have a non-representative or convenience sample. We also 
avoided including studies that evaluate measures at only one point in time or fail to include measures 
from pre- and post-implementation periods. Study design and methodology were an important 
component of this analysis. Our initial scan of the literature yielded many methodologically weaker 
studies that assessed outcomes of interest but were excluded for further review because they did not 
meet our methodological selection criteria. We have included all studies captured in our search in 
Appendix B, but we only assess outcomes of more rigorous studies in the body of this review. 
Our search strategy focused on databases of peer-reviewed articles and working papers. We 
searched Google Scholar and PubMed for peer-reviewed articles in English and the National Bureau 
of Economic Research for working papers. We identified papers written and/or published up until July 
2018, focusing on REC legalisation in the Americas; in addition six more recent peer-reviewed 
publications with credible control groups were added to the review during the publication process to 
ensure the findings were as up-to-date as possible (Kerr, D. et al., 2018; Anderson et al., 2019; 
Aydelotte et al., 2019; Cerdá et al., 2019; Everson et al., 2019; Lane and Hall, 2019) and insights from 
a new review (Smart and Pacula, 2019). Given that REC is a recent phenomenon, we concentrated 
our screening on articles published after 2012. The following search terms were used: recreational; 
marijuana or cannabis; and legalisation. We screened articles, focusing on evaluations relevant to 
REC and those that utilised methods that allowed for making inferences (e.g. pre-/post-analyses, 
interrupted time series, differences-in-differences). 
4.2 Prevalence of use 
Some analysts hypothesise that cannabis prevalence rates will change after recreational 
commercialisation (e.g. Caulkins et al., 2015; Hall and Lynskey, 2016). There are many reasons for 
                                                     
(8) The one exception was a series of studies looking at adverse events pre/post REC legalisation in Colorado. We opted to 
include these studies, as they provide unique assessments of health outcomes relative to MED and REC legislation adoption in 
that state. 
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this, such as changing norms regarding cannabis use behaviours, product innovation, reductions in 
price and advertising (if allowed). There is greater concern regarding potential increases in youth 
prevalence, given the impacts of cannabis on the developing brain and the finding that early initiation 
is associated with poorer outcomes later in life (Fergusson and Boden, 2008). However, the 
consequences of REC legalisation will probably depend on how policy is implemented and the degree 
to which underlying attitudes and trends may be associated with recent changes in a state’s medical 
cannabis policy. In turn, both medical and recreational policy changes may be a latent factor of 
underlying social attitudes regarding cannabis. Nevertheless, changes in supply, especially as it 
relates to access to cannabis through retail establishments and price, may have a greater impact on 
prevalence than a mere change in the law, which is why several have cautioned that the longer term 
effects of liberalisation policies may not be consistent with short-term effects (Caulkins et al., 2015; 
Cerdá et al., 2017). 
Prevalence estimates are some of the most referenced statistics about the consequences of REC 
legalisation. The prevalence of cannabis consumption measures the proportion of a particular 
population that self-report using cannabis within a certain period, typically in the last month, in the last 
year or during their lifetime. The federal and state governments regularly estimate prevalence rates 
for different age cohorts using household or school surveys. The National Survey on Drug Use and 
Health (NSDUH) and the Monitoring the Future (MTF) surveys are two well-known, nationally 
representative surveys that regularly report cannabis prevalence, frequency of use and perception of 
risk estimates by age groups. The NSDUH also reports pooled 2-year, state-level prevalence 
estimates by age group. In addition to these surveys, Colorado and Washington (9) have conducted 
their own state-wide prevalence surveys of high school students (Healthy Kids Colorado Survey — 
HKCS; and Washington state’s Healthy Youth Survey — HYS). Our scan of the literature also 
identified studies that evaluated changes in other repeated cross-sectional surveys, such as the 
National College Health Assessment survey or the National Alcohol Survey. 
Figure 4.1 plots the past-month cannabis prevalence rates for the five states that passed REC laws 
before 2016 and for the entire country (10). Table 4.1 is included as a reference, indicating when 
MED/REC laws were adopted and when stores opened (except DC, which remained ‘grow and give’ 
only). Almost all states report increases in prevalence rates among the general population post REC 
legalisation, though prior trends suggest an increase in states’ predated REC laws. Of course, simply 
examining trend data does not allow for strong causal inferences, and there is an emerging quasi-
experimental literature attempting to control contextual factors and isolate these policy effects. 
 
TABLE 4.1 
Dates of MED/REC adoption and implementation for selected states 
 Medical cannabis  Recreational cannabis 
State Adoption Year stores legally 
opened 
 Adoption Implementation 
Alaska November 1998 Not applicable  November 2014 October 2016 
Colorado November 2000 2005  November 2012 January 2014 
DC November 1998 2010  November 2014 February 2015 
Oregon November 1998 2009  November 2014 October 2015 
Washington November 1998 Not applicable  November 2012 July 2014 
 
                                                     
(9) We focus on these two states, given that there are more available post-treatment data, because recreational markets have 
been operating for over four years. 
(10) Additional trend data, including plots for individual states, are included in Appendix C. 
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FIGURE 4.1 
Prevalence of cannabis use in the past month (%) among people aged 12 years and older  
 
Source: NSDUH 
 
So far, the peer-reviewed literature reports mixed findings regarding changes in self-reported 
prevalence after the adoption of REC laws. Studies in this nascent literature focused on adults are 
more likely to find an increase than those examining younger populations; indeed, there are some 
studies suggesting that youth prevalence may have declined. Table 4.2 compiles and summarises 
these findings described below. 
Youth  
In terms of changes among students, Cerdá et al. (2017) reported significant declines in the 
perception of harm and significant increases in past-month use of cannabis among 8th and 10th 
graders in Washington compared with states that did not adopt REC laws. The study employed a 
difference-in-difference approach to compare past-month prevalence rates between 2010-12 and 
2013-15 in Colorado and Washington against rates in the rest of the US. The authors found that, in 
Washington, perception of harm reduced by 9 % for both grades (p < 0.02) and that past-month use 
increased by 5.0 (p = 0.03) and 3.2 (p = 0.007) percentage points for 8th and 10th graders, 
respectively (Cerdá et al., 2017). However, no significant difference in perception or use was reported 
for 12th graders in Washington or for any of the grades in Colorado. 
The study treated REC enactment and implementation as one policy change. Though the law 
changed after voters approved the initiatives, stores were not authorised to sell cannabis products to 
customers until after the implementation. The different trends in prevalence may also be an artefact of 
the different nature of the medical cannabis policy environments in Washington and Colorado, the 
latter having a robust commercial market and allowing un-registered caregivers to cultivate a large 
number of plants for registered patients. This finding may also be an artefact of the data used. Using 
survey data from a much larger sample of students in Washington (Washington’s Healthy Youth 
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Survey; HYS), Dilley et al. (2019) found that, if anything, there was a decrease in the past-month 
prevalence among 10th-grade students in Washington after REC enactment, according to state-wide 
surveys. Whether these results hold up when specific subgroups of students are examined remains to 
be seen. 
Using the individual-level NSDUH data with state identifiers from 2008-2016, Cerdá et al. (2019) 
found no evidence that REC enactment influenced the past-month cannabis prevalence for those 
aged 12-17. Although it should be noted that only three states (Colorado, Washington and Oregon) 
had implemented REC markets with open stores during the period of evaluation, and those had only 
been open for a relatively short period of time during their window of evaluation. Anderson et al. 
(2019) examined a longer time-frame (1993-2017) using the national and state Youth Risk Behavior 
Survey (YRBS) and reported there was no association between MED laws and past-month 
prevalence among students; however, they did find evidence suggesting prevalence may have 
declined for students after REC laws were enacted (11). We expect additional analyses will be 
conducted with these datasets that exploit additional changes in implementation of the state laws, 
information about per capita outlets and retail sales, and other aspects of the regulatory 
environments. The results thus far suggest that the mere passage of the laws does not affect youth. 
More research is needed to understand whether youth consumption is influenced by features of more 
mature cannabis markets, which are characterised by lower prices, product proliferation, and higher 
outlet density. 
College students 
In two studies of college students, D. Kerr et al. (2017, 2018) investigated changes in cannabis 
prevalence rates after REC enactment in Oregon. In their first study, authors collected responses from 
online surveys of students (aged 18 to 26) across seven universities, only one of which was in 
Oregon, between 2012-2016. Using these repeated cross-sectional surveys, authors found that 
cannabis use rates had increased across six of the seven universities over the time period, but the 
increase in use rates was significantly greater for students in Oregon that also reported recent heavy 
alcohol use (Kerr, D. et al., 2017).  
In another study using a different repeated cross-sectional survey of university students (ages 18-26) 
from 2008 to 2016, authors compared changes in self-reported cannabis use rates from two 
universities in Oregon and 123 universities and colleges from non-REC states. Authors found that, 
compared to the students in the other states, Oregon students showed a relative increase in rates of 
past-month cannabis use after REC law passage (odds ratio = 1.29 [1.13, 1.48]) (Kerr, D. et al., 
2018). 
Adults  
W. C. Kerr et al. (2018) analysed self-reported past-year cannabis use in Washington with a repeated 
cross-sectional random sample of adults aged 18 years and over from before the state implemented 
REC legislation but after it enacted it (wave 1: January to April 2014) and post implementation 
(wave 2: March to May 2015; wave 3: August to October 2015). Participants were also asked to recall 
their past-year cannabis use for the 12 months prior to REC enactment, which started in December 
2012. The authors found that respondents reported a small and non-significant increase in past-year 
use (from 24.3 % to 25.6 %) from the responses relating to the pre-enactment period to the combined 
average of all three post-enactment/implementation waves (Kerr, W.C. et al., 2018). They go on to 
state that there was no statistically significant change in the prevalence of the simultaneous use of 
alcohol. However, the study relies on participants’ recall of past-year use, prior to REC law enactment, 
which may not be accurate and is likely to be influenced by the state’s medical cannabis market. 
                                                     
(11) However, critics have raised concerns about merging national and state-representative samples from the YRBS for 
conducting analyses of the effects of any state policy, including medical and recreational cannabis laws. Doing so can lead to 
distortions of the sample in some states, which may affect the results obtained using these data (Jones et al., 2019; Rapoport 
et al., 2019). 
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Furthermore, the study does not clearly distinguish between REC enactment and implementation. The 
null effect reported may be due to the study’s design, such as relying on respondents’ memory. 
Without a suitable control group for comparison, it is hard to draw strong inferences. 
One cohort study analysed self-reported past-year use data from the repeated cross-sectional 
National Alcohol Survey of adults across the country between 1984 and 2015. The authors used an 
age-period-cohort design to assess changes in respondents’ past-year use across states that passed 
REC or MED laws or allowed home cultivation or operational dispensaries. The authors found that the 
underlying period effects were the main factor contributing to increases in self-reported cannabis use; 
the passage of REC laws, or laws allowing home cultivation of cannabis and the opening of 
dispensaries were not significantly associated with increases in prevalence (Kerr, W. C. et al., 2017). 
They noted that, though REC/MED policies were not associated with changes in prevalence, survey 
data show a decline in use during the 1980s and 1990s but a sharp increase from 2005 to 2015, 
varying by demographic and age cohort. The authors attributed recent increases in self-reported 
prevalence to general period effects that influence the greater population, rather than specific REC 
policies. Nevertheless, the authors noted that their design does not allow for an analysis of state-
specific trends. Furthermore, as their analysis covers a period of more than 30 years, it may be 
confounded by changes in social attitudes towards cannabis use. They noted that self-reported use 
may be affected strongly by legal and social norms, which might bias responses. 
The previously mentioned NSDUH analysis by Cerdá et al. (2019) looking at cannabis use among 
youth also examined whether enactment of REC laws influenced the prevalence rates for adults, 
broken down into two age groups: 18-25 and 26+. Similar to the findings for those under 18, they 
found no effect on the prevalence rates for cannabis use among those 18-25 after REC enactment; 
however, the results were different for the oldest group. The authors found that REC enactment was 
associated with an increase in the prevalence of past-month cannabis use among those aged 26 and 
over (odds ratio [OR], 1.28; 95 % CI, 1.16-1.40). 
While the significant within-state variation in how legalisation is being implemented can complicate 
state-year panel analyses, it does provide opportunities for learning more about how store density and 
other factors may influence cannabis prevalence and other outcomes. Merging information about 
recreational store addresses with location information for adults participating in Washington’s 
Behavioral Risk Factor Surveillance System from 2009-2016, Everson et al. (2019) found that past-
month cannabis use ‘increased among adults living in areas within 18 miles of a retailer and, 
especially, within 0.8 miles (odds ratio [OR] = 1.45; 95 % confidence interval [CI] = 1.24, 1.69).’ Of 
course, it would make sense that some stores would try to locate in places with more cannabis users, 
and the authors attempted to account for this by estimating generalised mixed models with a random 
intercept by community effect and a random time by community effect as well as controlling for a host 
of community-level (and individual-level) variables. The authors acknowledge that an important 
limitation is that the analysis does not account for the number of unlicensed medical cannabis outlets 
or ‘community gardens’ operating in the state before and after the REC law was passed; however, 
they argue this may have biased their results toward zero (12). 
Finally, one study examined self-reported past-month rates of use in two cohorts of pregnant women 
and young mothers in an alcohol and drug case management intervention programme before and 
after REC law enactment and implementation in Washington (comparing wave 1, February 2001 to 
November 2012, with wave 2, December 2012 to July 2015). The authors compared self-reported 
past-month cannabis use in samples of participants from nine populous counties in the state and 
found that women who completed the programme post REC law enactment (in or after December 
                                                     
(12) Everson et al. note: ‘Because we did not account for alternate sources, we overestimated the net proportional increase in 
cannabis access attributable to the retail market (although not for the law-abiding general public). Our findings may thus 
underestimate the potential effect of introducing retail access as compared with locations with smaller or less easily accessible 
medical and illicit markets.’ 
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2012) were significantly more likely to report cannabis use on exit (OR = 2.1, p < 0.0001) (Grant et al., 
2017). The authors went on to note that women who used cannabis during pregnancy in the post-
REC group were significantly less likely to quit than their counterparts in the pre-REC group (33.1 % v 
45.4 %, p < 0.01). However, the sample of this cohort study limits interpretability to at-risk young 
mothers and pregnant women attending a drug and alcohol outreach programme and does not 
include the larger population of young mothers. Furthermore, researchers ignored any different policy 
impacts between REC enactment and implementation. The reliance on self-reported data may 
introduce bias in a population of individuals referred to a drug and alcohol abuse intervention 
programme. The pre-REC population may have under-reported their cannabis use to avoid stigma 
and legal sanctions. 
The mixed results reported in the literature may be, in part, due to the variation in study design 
methods, sub-population selection and which cannabis policy change researchers are measuring over 
which time period. As noted, several studies seem to conflate REC law adoption, enactment and 
implementation. Even when voters approve a REC initiative, it can be one or two years before any 
cannabis is sold in stores. Along with lags in survey data, researchers, eager to evaluate the impacts 
of REC, may be incorrectly specifying when a change in policy occurred, particularly given the existing 
medical cannabis policies that are in place in all of these states that had legalised REC cannabis. 
Furthermore, the time periods analysed may yield different results. The inclusion of long pre-REC 
legalisation periods, which pick up the effects of MED cannabis provision, may return different results 
from studies over shorter pre-REC periods. Finally, studies that combine young people and adults, or 
at-risk populations and general household populations, may fail to pick up important heterogeneous 
effects that exist across these populations, as shown in studies examining the effects of medical 
cannabis policies (Chu, 2014; Pacula et al., 2015; Wen et al., 2015; Smart, 2016). 
In Table 4.2 we summarise the main findings of the four articles examining changes in prevalence 
rates post REC introduction that were discussed above. The remainder of the prevalence studies did 
not meet our inclusion criteria because of their research design, which lacked a suitable control, or 
because they were taken from convenience samples, they were cross-sectional or point-in-time 
measures or they failed to compare pre-REC outcomes with post-REC outcomes. 
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TABLE 4.2 
Summary table of peer-reviewed studies examining the effect of REC laws on cannabis 
prevalence  
Study Outcome evaluated Policy change Changes associated with policy  
Anderson et 
al. (2019) 
Prevalence rates in high school 
students 
REC/MED enactment 
across states 
No change in reported use after MED, 
possible decline after REC enactment 
Cerdá et al. 
(2017) 
Perception of harm and youth 
prevalence 
REC enactment and 
implementation in 
Colorado and Washington 
Reductions in perception of harm and 
increases in reported use for 8th and 10th 
graders in Washington 
No changes in perception or prevalence 
among 12th graders in Washington or 
young people in Colorado 
Cerdá et al. 
(2019) 
Prevalence rates and self-reported 
cannabis use disorder rates for youth, 
young adults, and adults 
REC enactment in 
Colorado, Washington, 
Alaska and Oregon 
No changes in prevalence rates for those 
ages 18-25. Increase in respondents 26 
years or older 
Dilley et al. 
(2019) 
Prevalence rates for secondary school 
students 
REC enactment in 
Washington 
Decrease in prevalence rates for 8th and 
10th grades 
Everson et 
al. (2019) 
Prevalence rates for adults REC enactment and 
implementation in 
Washington 
Increase in current use of cannabis for 
those that reported proximity to a retail 
outlet 
Grant et al. 
(2017) 
Changes in past-month rates of use in 
pregnant women and young mothers 
in an alcohol and drug case 
management programme 
REC enactment and 
implementation in 
Washington 
Significant increases in self-reported use 
Kerr, D. et 
al. (2017) 
Prevalence rates in college students REC enactment in 
Oregon 
No changes in prevalence rates for 
students in Oregon. An increase in 
cannabis prevalence rates for those also 
reporting recent alcohol binge drinking 
Kerr, D. et 
al. (2018) 
Prevalence rates in college students REC enactment in 
Oregon 
Increase in cannabis prevalence rates for 
students in Oregon 
Kerr, W. C. 
et al. (2017) 
Prevalence of adults  REC and MED enactment 
and implementation 
Increases in prevalence are attributed to 
underlying age-period-cohort factors and 
not a change in policy 
Kerr, W. C. 
et al. (2018) 
Prevalence of adults aged 18 years 
and over 
REC implementation in 
Washington 
No significant change 
4.3 Consumption patterns 
The implementation of REC laws may affect cannabis consumption patterns in two important ways: 
mode of administration and intensity of use. Commercial REC provision in the US allows promotion, 
product innovation and price competition. Each of these factors is expected to shape the way 
individuals consume the drug — how, where, when and how much. Product innovation allows the 
substance to be consumed in edibles or vaporised through the use of an electronic cigarette. 
Improved cultivation methods are shaping the potency of cannabis sold in REC markets, resulting in 
consumption of higher THC levels and with variations in cannabinoid profiles. The rate and amount of 
THC that regular users consume is likely to be shaped by changes in price and availability made 
possible by commercial REC markets. 
Nationally, the average number of days of use in the past month reported by past-month users 
increased from 12.4 to 14.5 between 2003 and 2017 (SAMHSA, 2018). Figure 4.2 displays the 
percentage of past-month users who reported daily or near-daily use (i.e. > 20 use days in the past 
month) by state and for the entire country. For the entire country, the rate increased from 33.4 % to 
41.7 % between 2003 and 2017. State estimates of daily or near-daily use have not been tabulated 
beyond 2014, but a similar increasing trend is reported for most states. In 2014, approximately half of 
past-month users in Colorado and Oregon reported using cannabis on 20 or more days, up from 38 % 
and 37 %, respectively, in 2009. 
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FIGURE 4.2 
Past-month cannabis users aged 12 years and over using on a daily or near-daily basis (%) 
 
Source: NSDUH 
The previously mentioned study by Everson et al. (2019) which exploited variation in recreational 
store density in Washington state not only found that those who lived within 0.8 miles (1.3 km) of a 
store were more likely to report use in the past month, they also found that these individuals were 
much more likely to report daily or near-daily cannabis use. 
In addition to using individual-level NSDUH data to examine the association of REC enactment with 
prevalence of cannabis use, Cerdá et al. (2019) also examined the association with frequency of past-
month use and past-year cannabis-use disorder (CUD). With respect to frequency of use, they only 
found a statistically significant increase associated with those aged 26 and older. As for CUD, there 
appears to be a small and statistically significant increase for youth, but the authors cautioned that 
they could not rule out that unmeasured time-varying confounders may explain this finding (13). But for 
those aged 26 and over, they report a statistically significant increase in past-year CUD and that there 
was less concern that unobserved confounding may explain the association.  
4.4 Product differentiation and price 
As mentioned in the previous section, commercial REC has brought with it product innovation. Such 
product differentiation and promotion, in turn, shape user behaviour and consumption. Cannabis 
flower is still the dominant form of cannabis consumed in REC markets, but trends in data collected as 
part of the seed-to-sale traceability systems in REC states suggest that new products that allow for 
various modes of administration (vaporising, edibles and topicals) account for an increasing 
proportion of sales. In one analysis of market trends in Washington, researchers analysed all 
recorded retail sales (36 million observations) for a little more than two years (July 2014 to September 
2016) (Smart et al., 2017). Researchers found that there were important changes in product type, 
potency and price. Figure 4.3 is an updated reproduction from Smart et al. (2017), showing the  
                                                     
(13) Specifically, Cerdá et al. (2019) note: ‘E-value analyses suggested that unmeasured time-varying confounders 
hypothetically more prevalent in [REC]states that increase the risk of cannabis use slightly (1.08-1.11 times) may explain this 
finding. The extent to which such confounders exist is unclear because our difference-in-difference design accounted for 
unmeasured time-invariant sources of confounding and also adjusted for measured time-varying individual- and state-level 
demographic characteristics. However, the small E-values warrant a conservative interpretation of the increase in CUD among 
participants aged 12 to 17 years.’ 
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FIGURE 4.3 
Washington’s cannabis sales by product type after 37 % excise tax (million USD) 
Source: RAND analysis updating Smart et al. (2017) 
 
increasing trend in sales of edibles and vaporisable products, which grew to roughly one third of total 
sales expenditures by mid-2017. 
In terms of potency, an analysis of transaction data (included in the article but not shown here) shows 
that the reported potency of cannabis flower, as measured by state-accredited laboratories, has 
increased. The proportion of strains with reported THC concentration greater than 15 % grew to 93 % 
by September 2016; cannabis flower of less than 10 % THC potency accounted for less than 2 % of 
expenditures. The authors noted that cannabis flower with more than 20 % reported THC has 
increased by almost half since October 2014, accounting for 57 % of the retail expenditures (Smart et 
al., 2017) (14). As for price, it is hard to know what consumers would have faced in the absence of 
REC legalisation but, as predicted, prices are falling. Updated analyses of Smart et al. (2017) and by 
Davenport (unpublished) show that the average post-tax price for 1 g of cannabis flower fell from 
roughly USD 20 in October 2014 to USD 10 in October 2015 and USD 7 in October 2017, and it 
continues to decline (15). 
A smaller study of MED and REC cannabis users from Washington and Colorado (n = 317) and a 
web-scraping analysis of prices listed on Weedmaps (n = 3 802) compared user-reported and 
dispensary-advertised prices of cannabis in both states during REC enactment periods with prices 
after implementation (wave 1, October 2013; wave 2, May 2014; wave 3, October 2014). The authors 
found that there was little price variation in the initial months post REC implementation but that 
individuals reported paying higher prices for in-store purchases than for social purchases (Hunt and 
Pacula, 2017). However, the authors noted that a limitation of the study is the very short time period 
post REC implementation (within five months of stores opening). As noted above, other researchers 
(Hansen et al., 2017a; Smart et al., 2017; Orens et al., 2018) have shown that prices do decline over 
                                                     
(14) We note that the potency reported by retailers may not be accurate. For example, initial studies of results from laboratories 
in Washington show that there are clear systematic differences in potency results across laboratories but that general potency 
results are inflated (Jikomes and Zoorob, 2018). State regulators have made efforts to address reporting biases.  
(15) Price drops have also been documented in Colorado. A new study by Orens et al. (2018) reports that, from 2014 to 2017, 
‘the price of one gram of adult use flower exhibited a steady downward trend, decreasing 62.0 percent, from $14.05 to $5.34 
per gram’ (pre-tax). 
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long periods of time, providing a strong indication that the immediate effects of these policies may be 
different from outcomes in the longer term. 
Our literature review did find two studies examining the promotion of REC cannabis products, but 
these were excluded from further analysis, as they did not evaluate trends before and after REC 
implementation. 
4.5 Treatment admissions 
It is hypothesised that commercial REC legalisation will change the intensity and frequency with which 
individuals consume cannabis. This includes consuming cannabis more frequently as well as 
consuming products with a higher potency. These factors may lead to cannabis use disorder and thus 
increase the number of treatment admissions. However, it may take years for a cannabis use disorder 
to develop, suggesting that any immediate changes in admissions may reflect the impacts not of REC 
legalisation, but perhaps of MED use. At the same time, cannabis possession and use are no longer 
criminal offences once REC laws have been adopted. Therefore, we would expect reductions in 
criminal justice referrals to treatment for cannabis after the adoption of REC. A more general point is 
that treatment admissions data are also influenced by the availability and perceived attractiveness of 
services and reporting and diagnostic practices, all of which can vary over time. However, no studies 
investigating changes in treatment admissions were identified during our review. 
4.6 Adverse medical events 
Under the assumption that REC legalisation increases consumption, a proportion of this type of 
cannabis use may result in an adverse event (e.g. an overdose that results in an emergency 
department (ED) visit or hospitalisation) (16). Accidental ingestions or overdoses, especially by young 
children, may result from the supply of certain products, such as edibles that look like traditional 
sweets. Regulators in Colorado and Washington promulgated emergency regulations to improve 
labelling and warnings as well as educate the public about the potential effects of new products, some 
of which are meant to look like benign consumables. 
We identified eight articles that looked at changes in various adverse events (such as hospitalisations 
or ED episodes) before and after (pre and post) MED/REC and their relationship with MED/REC 
legislation. All articles examine outcomes in Colorado over various periods, some including MED 
treatment periods. All were pre/post studies without any comparison groups, and may be subject to 
self-reporting biases (e.g. individuals may be more likely to report cannabis use or seek medical 
attention post REC). Therefore, caution should be exercised when interpreting their findings. 
Significant differences were assessed using standard non-parametric hypothesis testing for all 
studies. Two of the eight studies examined paediatric or child exposures to cannabis. All of them 
examined hospital data assessing the impact of changes to Colorado’s MED and REC laws. These 
studies report an increased frequency of adverse events post REC enactment or implementation, and 
some have observed an increase prior to the adoption of REC, attributing this to lenient MED policies. 
However, several studies compare different pre and post periods, which in some cases are not 
immediately before or after the adoption of REC (comparing, for example, per capita rates of events in 
2009 and in 2015). 
Two studies compared paediatric cannabis exposures necessitating medical attention in Colorado 
before and after MED or REC implementation. Both studies found statistically significant increases in 
the frequency of such events following changes in legislation. Wang et al. (2016) report that the rate 
of cannabis-related visits to the children’s hospital increased from 1.2 per 100 000 residents 2 years 
prior to REC implementation (2012/2013) to 2.3 per 100 000 residents 2 years after (2014/2015) 
                                                     
(16) An ED visit is recorded when an individual presents to a hospital for emergency care but is not admitted for observation or 
treatment. A hospitalisation is recorded when a patient is admitted for observation and treatment. 
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(p = 0.02). The same study found a fivefold increase in annual poison control (17) paediatric cases for 
cannabis exposures (from nine in 2009 to 47 in 2015) post REC implementation (18). This amounted 
to an average annual increase in calls to Colorado poison control centres for cannabis of 34 %, 
significantly more than the national average of 19 % (p < 0.001). In another retrospective study of 
cannabis-related ED visits, Wang et al. (2018) found that cannabis-related ED visits increased from 
1.8 per 1 000 in 2009 to 4.9 per 1 000 in 2015 (p  =  < 0.0001). Though rates increased, it is hard to 
say what policy mechanism led to their increase. Cannabis policy in Colorado went through several 
transformations between 2009 and 2015, including the adoption of several laws and voter initiatives 
that formalised commercial markets. 
Kim and Monte (2016) examined hospitalisation incidents coded for cannabis exposure between 2001 
and 2014, collected by the Colorado Hospital Association, to compare before and after MED and REC 
implementation. The authors found that cannabis-related hospitalisations doubled from 15 per 
100 000 between 2001 and 2009 (the pre-MED commercialisation period, when dispensaries were 
operating) to 28 per 100 000 between 2010 and 2013 (the post-MED commercialisation period) 
(p < 0.001) (Kim and Monte, 2016). The authors noted that this statistically significant doubling 
occurred after MED implementation. They then examined rates of cannabis-related ED visits between 
pre- and post-REC implementation, reporting that the figure nearly doubled from 22 per 100 000 
(2010-13) to 38 per 100 000 (January-June 2014) (p < 0.001). 
Using a shorter time period, Kim et al. (2016) examined ED visits for cannabis from 2011 to 2014. The 
authors reported no significant change from 2011 to 2012 in the rate of ED visits with ICD-9 codes of 
cannabis use among out-of-state residents, which is possible given that MED is restricted to in-state 
residents. However, from 2012 to 2014, the state-wide rate among out-of-state residents rose from 78 
per 10 000 visits in 2012 to 112 per 10 000 visits in 2013 and 163 per 10 000 visits in 2014 (p < 0.001 
for all comparisons). Among Colorado residents, the rate of ED visits possibly related to cannabis use 
per 10 000 visits increased from 61 in 2011 to 101 in 2014 (p < 0.001) (Kim et al., 2016). By 
comparing year-on-year changes, the authors sought to determine the association with changes in 
REC enactment and implementation. ED data suggest that the rate of adverse events continued to 
rise over the period, starting in 2011, perhaps because of the expansion of commercial medical 
markets. 
One study looked at annual rates of hospitalisations, ED events and calls to Colorado’s poison control 
centres between 2000 and January to September 2015. Wang et al. (2017) reported that cannabis-
related hospitalisations increased from 274 to 593 per 100 000. Examining trends over time, Wang et 
al. (2017) found a year-on-year increase in cannabis-related hospitalisations over a period starting in 
2009 and ending in September 2015. The rates of ED visits also increased year on year, starting in 
2011 (the first year for which data were available). The rates of ED visits significantly increased from 
2012 to 2013 (358 v 443 per 100 000; p = 0.003) and from 2013 to 2014 (443 v 554 per 100 000; 
p = 0.0005). The prevalence of mental illness diagnoses in cannabis-related ED visits was five times 
higher than the prevalence among those whose ED visits were not cannabis-related, and the 
equivalent figures for hospitalisations showed a ninefold higher prevalence of mental illness 
diagnoses among hospitalisations that were cannabis-related. Calls to poison control centres, 
although flat between 2000 and 2009, increased significantly, from 44 to 93 in 2010 (p < 0.0001), and 
again jumped from 123 to 221 (p < 0.0001) between 2014 and 2015 (Wang et al., 2017). The sharp 
and sustained increase in adverse events began right around the time when MED commercial 
dispensaries were formalised (around 2010) and continued throughout the adoption and 
implementation of REC in 2014. 
                                                     
(17) Calls to poison control centres can be made by patients, the general public or medical professionals. In the US, there are 
about 2 million exposure calls per year, approximately a quarter of which come from a healthcare facility.  
(18) As a point of reference, Colorado Poison Control reported over 25 000 exposures for those under the age of 19 years 
between July 2015 and June 2016. 
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ED visits for cannabis-related mental health diagnoses also increased in Colorado post REC. Similar 
to Wang et al. (2017), K. E. Hall et al. (2018) reported that, post REC implementation, the prevalence 
of mental health diagnoses in cannabis-associated ED visits was five times greater than the 
prevalence in ED visits not related to cannabis (prevalence ratio 5.35, 95 % confidence interval (CI) 
5.27 to 5.43). The rate of ED visits in Colorado associated with both cannabis and mental health 
significantly increased from 224.5 per 100 000 in 2012 to 268.4 per 100 000 in 2014 (p < 0.0001) 
(Hall, K. E. et al., 2018). 
In an analysis of ED events in Denver between 2012 and 2015, Sokoya et al. (2018) reported that the 
number of maxillary and skull base fractures increased post REC implementation (2012-13 v 2014-15) 
(p < 0.001 for both outcomes); however, counts of other facial/cranial fractures were unchanged. Bell 
et al. (2015) examined cases of burns related to hydrocarbon exposure likely to be related to the 
home production of butane hash oil extractions from January 2008 to August 2014, before and after 
Colorado implemented its MED and REClaws. The authors reported no cases prior to MED 
implementation, 19 cases between October 2009 and December 2013 and 12 cases in 2014, after 
REC implementation (Bell et al., 2015). Although not reported, the average monthly rate increases 
from zero in the pre-MED period to 0.37 during MED implementation and to 1.75 per month during 
REC implementation. Unlicensed extractions using an ‘inherently hazardous substance’ were 
subsequently criminalised in Colorado. 
Though studies report increases in adverse events, it is possible that some increases could be due to 
changes in reporting or measurement. For example, it is unclear if increases in ED visits and 
hospitalisations are due to a greater willingness on the part of individuals to report use of cannabis 
and/or if doctors are more aware of acute cannabis intoxication post REC and are now more likely to 
screen for or confirm cannabis use using urinalysis. 
4.7 Impaired driving 
Changes in cannabis policy may affect impaired driving outcomes (such as accidents or citations for 
driving under the influence) in multiple ways. While the bulk of the research suggests that driving 
while under the influence of alcohol is more dangerous than driving under the influence of cannabis, it 
also suggests that driving under the influence of cannabis is more dangerous than driving sober 
(Caulkins et al., 2016). It is possible that impaired driving outcomes may change after the 
implementation of REC, depending on whether cannabis becomes a substitute for or complements 
alcohol consumption; however, there is mixed evidence as to the relationship. In our review, we 
identified two studies that evaluated motor vehicle fatalities and one that examined reported insurance 
claims. 
One peer-reviewed study examined the impact of REC on motor vehicle crash fatalities in Washington 
and Colorado and neighbouring states that did not pass REC but were substantially similar in terms of 
traffic and roadway characteristics from 2009 to 2015. Researchers analysed changes in the annual 
number of vehicle fatalities reported in the Fatality Analysis Reporting System (FARS), using a 
standard difference-in-difference approach with random effects. They then compared four years of 
pre-REC adoption (2009-12) outcomes with three years of post-REC enactment and implementation 
outcomes (2013-15). The analysis found no statistically significant difference in fatal crashes between 
REC and non-REC states (+0.2 fatalities/billion vehicle miles travelled; 95 % CI −0.4 to +0.9) 
(Aydelotte et al., 2017). However, the authors noted that their policy specification conflates REC 
enactment and REC cannabis commercialisation, as they used the date the REC law was passed, not 
the date when stores opened. 
A National Bureau of Economic Research working paper (Hansen et al., 2018) employing synthetic 
controls also assessed the impact of REC on motor vehicle crash fatalities in Washington and 
Colorado and all states that did not adopt a REC law between 2000 and 2016. The authors found 
that, between 2013 (the last year before REC implementation) and 2016, drivers testing positive for 
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THC (19) increased in Colorado and Washington by 92 % and 28 %, respectively. However, the 
authors concluded the following: ‘We find the synthetic control groups saw similar changes in 
marijuana-related, alcohol-related and overall traffic fatality rates despite not legalising recreational 
marijuana’. 
Two more recent studies find evidence of an increase in traffic fatalities after legalisation. In a follow-
up study, Aydelotte et al. (2019) added additional years from the FARS database, comparing monthly 
crash data from 2007 to 2017 in Colorado and Washington, which passed REC laws in 2012, against 
five other states with MED laws, and four that did not change any cannabis laws. The authors also 
examined changes in rates after opening of stores in Washington and Colorado in 2014. Aydelotte 
and colleagues reported that the fatal crash rate in Washington and Colorado increased by 1.2 
crashes (p = 0.087) per billion vehicle miles travelled after REC enactment, but that there was a 
statistically significant and larger increase after opening of stores (an increase of 1.8 crashes per 
billion vehicle miles; p = 0.02). The results are sensitive to stores opening, supporting evidence that 
REC implementation, rather than mere passage, may correlate with outcomes. 
In another quasi-experimental analysis, Lane and Hall (2019) examined monthly traffic fatalities 
between 2009 and 2016 in Colorado, Washington and Oregon compared to nine neighbouring 
jurisdictions that did not change cannabis laws. Authors specified the opening of dispensaries as the 
treatment condition instead of REC passage or enactment. They found that store openings were 
associated with an immediate increase in 1.08 traffic fatalities per million residents followed by a trend 
reduction of 0.06 fatalities per month (both p < 0.001). There was a similar step-up increase and 
declining trend in both treatment states (step: 0.90, P < 0.001; trend: −0.05, P = 0.007) and 
neighbouring jurisdictions (step: 1.15, P = 0.005; trend: −0.06, P = 0.001). They concluded that:  
The results suggest that legalizing the sale of cannabis for recreational use can lead to a 
temporary increase in traffic fatalities in legalizing states that can spill over into neighbouring 
jurisdictions. 
In another widely cited report, published by the Highway Loss Data Institute, authors compared auto 
insurance collision claim rates (not necessarily fatalities) in Colorado, Washington and Oregon with 
those in neighbouring states (Nebraska, Utah, Wyoming, Montana, Idaho and Nevada) that did not 
adopt REC, from January 2012 to October 2016. The analysis found that collision claim frequencies 
increased significantly by a combined rate of 2.7 % after REC implementation (Highway Loss Data 
Institute, 2017). 
The mixed results reported in the earlier studies identified are likely to be due to the difference in 
outcomes evaluated, the specification of the REC policy change or the analytic methods employed. 
Aydelotte et al. (2017) and Hansen et al. (2018) examined motor vehicle crash fatalities but with 
different exposure variables (the latter was REC implementation, the former REC enactment); the 
report by the Highway Loss Data Institute (2017) examined insurance claim data and the relationship 
with REC implementation. Neither of the motor vehicle fatality studies found a relationship between 
the fatality rates and REC. However, the report examining insurance claims did find a significant and 
positive relationship, but one that does not negate findings from other papers. It is possible that non-
fatal accidents increased over this period, even if fatal accidents did not.  
In the more recent analyses reported here, Aydelotte et al. (2019) and Lane and Hall (2019) examine 
the relationship with motor vehicle fatalities and the opening of REC dispensaries. Both studies found 
a positive relationship between opening of stores and motor vehicle deaths. These findings suggest 
that the appropriate policy change to consider in evaluations is opening of stores, when product 
becomes commercially available, instead of mere changes in the law. 
                                                     
(19) However, testing positive for THC is not an appropriate measure for impairment, as THC metabolites may remain in the 
system long after the subjective and objective effects of intoxication have abated (EMCDDA and CCSA, 2018).  
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Another possible reason for the inconsistency is the difficulty in identifying impairment at the time of 
an accident. Current methods reported in traffic fatality and insurance claims data are not sufficient to 
identify, among drivers who may have consumed cannabis within a specified time period before the 
accident, those who were actually impaired. Until such technology is developed and widely adopted in 
current reporting transport databases, we may not be able to sufficiently identify effects from 
observational data. 
4.8 Consumption of other substances 
The use of cannabis may substitute for or complement other psychoactive substances. There have 
been studies examining the relationship between the use of cannabis and alcohol, tobacco or other 
drugs; however, most of these studies have evaluated the relationship in users of illicit cannabis. REC 
and MED legalisation may substantially change the relationship or cannabis users’ access to other 
drugs. There are relatively few studies examining the effect of licit cannabis on the use of other 
substances or associated behaviours. Several studies have examined the population-level outcomes 
associated with access to medical cannabis. It is important to consider the changes that REC may 
have on the use of other substances. Social norms and commercial promotion of cannabis may make 
the use of this drug more appealing to individuals who would have otherwise consumed alcohol in a 
social setting. Likewise, there is an ongoing discussion in the US on using cannabis as a substitute for 
riskier opioid analgesics to treat chronic pain (Hall, W. et al., 2018). 
Several studies that examined the relationship with cannabis and other drugs are discussed in the 
table in the Appendix. Yet an extensive and recently published review of this literature by Smart and 
Pacula (2019) found complex and inconclusive results depending on the substance evaluated and 
measure used. They concluded: 
Evidence of the impact of cannabis liberalization on the use of other substances is 
inconclusive. We have limited evidence of how alcohol or tobacco use has been impacted, 
and despite a broader literature evaluating the impact of cannabis laws on opioid-related 
outcomes, the findings from this literature are puzzling. Studies assessing impacts on self-
reported misuse and distribution of opioids show no impact of [MED laws], yet studies 
evaluating opioid-related adverse events and opioid prescribing show reductions. Opioid-
related mortality, which early studies suggested was reduced by [MED laws], now appears to 
be positively correlated with these policies and the adoption of [REC laws]. The significant 
policy action being taken to combat the opioid crisis as well as the evolution of the types of 
opioids driving opioid-related harm likely contributes to the lack of robust findings for this 
outcome. 
4.9 Criminal justice and public nuisance outcomes 
The implementation of REC is likely to affect criminal justice and other public nuisance outcomes in 
multiple and divergent ways. There are concerns about drug-induced crime and disorder, such as 
acquisitive crime, vagrancy and public consumption. Likewise, REC may alter the broader systemic 
elements associated with crime, including illicit trade and violence. For example, REC legalisation 
could potentially lead some illicit distributors to other forms of crime, and unregulated processing that 
causes explosions pose a public safety hazard; however, we are not aware of any studies examining 
this. For some of these concerns, it is more than likely that the effects are mixed. For example, police 
are no longer tasked with enforcing laws prohibiting the possession of cannabis but are now required 
to stop and detain cannabis-impaired drivers. Some of these criminal justice outcomes are specific to 
the policy choices found in the US. For example, under federal prohibition, cannabis businesses 
cannot access the banking system and must deal almost exclusively in cash, making them a target for 
robberies. 
However, there are limits to interpreting law enforcement data. Reports may not be complete or 
reflective of the change in outcomes. They also may be confounded by changes in policy directives or 
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attitudes of individual officers. Post REC, public consumption may become more prevalent but under-
enforced as the public and law enforcement feel less compelled to intervene in minor infractions. As a 
result, evaluating counts of public consumption citations may not reflect the true magnitude of 
violations of the law with regard to using cannabis in public. Many other common ‘quality of life’ 
policing tasks are under-enforced. Cities have laws against littering, but these are often arbitrarily 
enforced by police officers, as this is sometimes seen as a poor use of police time. Likewise, changes 
in the estimates of intoxicated motorists may be a result not of REC per se but of changes in law 
enforcement directives and training aimed at detecting impaired driving. 
The studies evaluated here report mixed findings. Some suggest that REC is associated with 
increases in some crimes but unrelated to changes regarding other crimes. This largely depends on 
the stage at which the policy is evaluated (enactment v implementation) and where. Several studies 
found that REC is associated with increases in cannabis-specific crimes (e.g. possession, sales) in 
neighbouring non-REC states, suggesting that individuals may be moving cannabis over state lines. 
Using Denver police data on crime reported by census tract, one study compared rates of violent, 
property and cannabis-related crimes (defined as public consumption, robbery of a cannabis facility, 
unauthorised distribution, etc.) during MED/REC in Colorado (from January 2013 to October 2015) 
and examined whether or not they were related to the density of cannabis outlets. Freisthler et al. 
(2017) reported that the density of cannabis outlets was not associated with property or violent crimes 
in local areas, but the density of outlets was positively correlated with property crime in spatially 
adjacent areas over time. Likewise, the density of outlets was associated with higher rates of reported 
cannabis-specific crime in the same and neighbouring census tract (Freisthler et al., 2017). 
Nevertheless, this analysis was not able to assess the relationship between unregistered caregiver 
growers or home growers and incidents of crime. Furthermore, without an interrupted time series and 
in the absence of controls, authors can only report a correlation with crime and dispensary density. It 
is also possible that changes in law enforcement capacity and training may have confounded the 
analysis. 
At a more aggregated level, an interrupted time series study examined violent and property crime 
clearance rates (i.e. rates in which a charge was made for a reported crime) each month from the 
Federal Bureau of Investigation’s (FBI’s) uniform crime report data for Colorado and Washington, 
compared with the US as a whole, from 2010 to 2015. Makin et al. (2018) estimate that REC 
enactment in Colorado and Washington is associated with increases in police clearance rates for both 
property and violent crime. This is the appropriate policy indicator, as criminal penalties for 
possession and use were removed from the penal code on enactment. The authors employ an 
autoregressive integrated moving average (ARIMA) model to control for seasonality effects in 
robustness checks, reporting that their findings hold. Without measuring the mechanism of action 
precisely, they attribute REC enactment to potentially increasing clearance rates by shifting 
enforcement priorities in the field. 
One working paper compared FBI arrest data from the uniform crime report in counties in Washington 
and Colorado with those in neighbouring states from 2009 to 2014. The authors looked at arrests for 
driving under the influence (DUIs) and various drug-related offences in relation to REC enactment and 
implementation (2009-12 v 2013-14). They found that counties bordering Colorado saw an increase of 
about eight cannabis possession arrests per 100 000 compared with non-bordering counties post 
REC enactment and implementation; this was greater for counties bordering Washington, which saw 
an increase of 22.9 arrests per 100 000 compared with non-bordering counties (Hao and Cowan, 
2017). Reported arrest rates diminish the further the county is from the state borders of Washington or 
Colorado, suggesting that cross-state diversion is occurring. However, law enforcement agencies 
near the border may have shifted enforcement priorities (e.g. targeting out-of-state motorists), 
potentially confounding such an analysis. 
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When examining arrests for other drug-related offences (possession of other narcotics, distribution of 
cannabis or DUIs), the authors reported no association between counties bordering a REC jurisdiction 
and non-bordering counties post REC enactment and implementation. Nevertheless, the study 
conflates the REC periods of enactment and implementation. It is more likely that cross-state 
diversion would have occurred during the implementation period, after stores were opened than 
immediately following enactment. However, their findings show mixed results. Rates of cannabis 
possession arrests in counties bordering Colorado increased just prior to enactment in 2012, declined 
in 2013 and increased again during implementation in 2014. In Washington, arrest rates in 
neighbouring counties declined prior to enactment in 2012, increased in 2013 and then declined 
during the first year of implementation in 2014. Such divergence could be explained by the fact that 
jurisdictions neighbouring Washington have greater access to cannabis, with Oregon adopting a REC 
law in 2014. 
Another working paper examined Washington state recreational cannabis transaction retail data to 
assess potential interstate trafficking between Washington and Oregon (Hansen et al., 2017b). 
Washington implemented its REC in July 2014, whereas in neighbouring Oregon stores did not offer 
recreational cannabis to adults until October 2015. Hansen et al. assessed the impact that REC 
implementation in Oregon had on sales of cannabis on the Washington side of the border. They also 
reported that retail sales near the border in Washington declined by 41 % immediately after REC 
implementation in Oregon (Hansen et al., 2017b). The authors suggest that a substantial amount of 
demand for cannabis in Washington may have originated in Oregon, resulting in considerable 
interstate trafficking prior to REC implementation in that state. 
4.10 Tax revenues 
No studies have evaluated changes in cannabis policy and its impact on overall tax revenues (not just 
those that are associated with cannabis excise taxes and fees); however, state regulators regularly 
report sales and revenue data post REC. In Table 4.3, we report annual sales revenue and tax 
receipts. Colorado’s figures are for the calendar year (CY) and Washington’s are for the fiscal year 
(FY), which runs from July to June (2016 = July 2015 to June 2016). Retail cannabis sales surpassed 
a billion dollars in Colorado in 2016 and in Washington in 2017. Sales and tax receipts have 
increased year on year (with the exception of 2018, for which the information is partial). 
 
TABLE 4.3 
Cannabis sales and tax revenue 
 Colorado  Washington** 
Year 
Sales (CY) 
(million USD) 
Tax receipts (CY) 
(million USD) 
 Sales (FY) 
(million USD) 
Tax receipts (FY) 
(million USD) 
2014 683.5 67.6  0 0 
2015 995.6 130.4  259.5 64.9 
2016 1,307.2 193.6  786.4 185.7 
2017 1,507.7 247.4  1,371.9 314.8 
2018 1,545.7 266.5  Not reported 362.0 
2019* 386.7 63.5  Not reported Not reported 
*January to March for Colorado. 
**Recreational only. 
Sources: Colorado Department of Revenue, ‘Marijuana tax data’; Washington State Liquor and Cannabis 
Board, Marijuana Dashboard reports sales and tax receipts throughout 2017; Washington State Liquor 
and Cannabis Board annual report FY 2018 reports total tax receipts for that year. 
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4.11 Public opinion 
Our search found several studies that evaluated public opinion of REC. However, none of them met 
our inclusion criteria, because they were point-in-time estimates, they failed to include pre-REC 
measures or they were non-representative. That said, the longest running nationally representative 
survey asking Americans if they think the ‘use of marijuana should be made legal’ has shown a 
steady rise in positive responses since the mid-1990s. In 1996, one out of four Americans supported 
making the use of cannabis legal. By 2012, support had hit 50 %, and this rose further, to 66 %, in 
October 2018 (McCarthy, 2018). However, the poll asks about ‘use’, giving less indication as to 
respondents’ opinions on commercial legalisation. Nonetheless, most commercial legal REC models 
have been a result of popular voter initiatives. 
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5. Issues to consider when establishing a comprehensive
monitoring and evaluation framework for changes to cannabis
regulations
As discussions about cannabis policy intensify (Hughes et al., 2017), policymakers are in a unique 
position to learn from the experiences of cannabis reform in the Americas. Doing so, of course, 
requires an understanding of the motives or goals for the policy changes that occurred in that region 
and the extent to which the policy changes have in fact achieved their stated goals. However, such an 
understanding can only be achieved through actual measurement of the outcomes associated with 
these stated goals of the policy reform, both before and after implementation. States in the US that 
are adopting recreational cannabis laws often argue that such reforms will improve civil liberties and 
generate tax revenues (Hall and Kozlowski, 2018). There is less emphasis placed on public health 
and safety goals in the US than in the national discussions in Uruguay and Canada. Researchers 
note that many jurisdictions have not paid adequate attention to the measurement and monitoring of 
critical outcomes that are relevant to understanding the impact that REC may have on public health 
and safety. Without establishing a robust baseline measurement prior to the policy changes, it is 
difficult to accurately determine the causal impact of such reforms (including unintended 
consequences) or if they met their intended objectives. 
This is perhaps the greatest lesson that policymakers can learn from the early assessments 
conducted thus far — the need to consider, measure and monitor public health and safety objectives 
associated with cannabis policy reform before policy changes are implemented. Doing so requires 
considering all of the potential objectives of cannabis reform that a country may wish to achieve as 
well as the possible unintended consequences of such changes. Only then is it possible to identify 
metrics that can be used to assess changes and begin collecting baseline data. Moreover, as 
discussed in Section 3, many models of cannabis reform are available, and the regulatory model 
adopted will depend on the specific objectives of the policy change and will also influence the 
baseline and follow-up data that will be appropriate to assess if the objectives have been achieved. 
This section offers insights into creating such a comprehensive framework. We begin with a taxonomy 
of potential objectives that jurisdictions might seek to achieve (or harms to avoid) with cannabis 
reform, mapping them to specific outcomes that can be used as metrics for monitoring and evaluation. 
Since many of these measures are not currently collected, Section 5.2 offers some ideas for creating 
a data infrastructure to collect them. Section 5.3 offers insights into evaluating changes. 
5.1 Potential objectives of cannabis policy change and metrics of evaluation 
Discussions of cannabis policy change should begin with a clear understanding of objectives. 
Table 5.1 provides a taxonomy of potential policy objectives mentioned in jurisdictions that have 
recently reformed cannabis laws. These are based on communications with policymakers as well as 
statements made by proponents of ballot initiatives in US states that have recently voted on such 
initiatives. The stated objectives are to reduce crime and improve civil liberties, to promote public 
health and to generate economic activity and tax revenues. While not exhaustive, the examples 
provided in Table 5.1 provide a sense of what might motivate a jurisdiction to reform its cannabis laws 
and give us the opportunity to consider metrics for measuring the outcome of such a policy change. 
However, it should be noted that, as illustrated above, the evidence of whether or not these regulatory 
changes can achieve these outcomes is not yet available. 
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TABLE 5.1 
Statements commonly made by proponents of cannabis law reform 
Crime/public safety and civil 
liberties 
Reduce/eliminate the illicit market and related crime 
Re-prioritise law enforcement resources  
Reduce burden on criminal justice system 
Reduce criminalisation of non-violent drug offenders 
Reduce racial or ethnic disparities; correct for injustices of drug prohibition 
Health Make cannabis-based products available for medicinal purposes  
Allow for more research on medicinal benefits 
Reduce youth access and consumption 
Minimise contaminants and ensure product quality 
Offer more information to users on potency and harms 
Improve precision in dosing and potency 
Make it easier to talk about cannabis-related problems  
Reduce use of other potentially more dangerous products (alcohol, opioids) 
Prevention Limit availability by regulating licensees and store operations 
Economic/budget Increase government revenue through taxation and licensing fees 
Reduce cost of prohibition on criminal justice system 
Create new jobs in the legal economy (eliminate illicit market jobs) 
Normative Government should not control what someone puts in their own body 
Prohibition lacks legitimacy 
Similarly, a comprehensive evaluation of any policy change must consider the possibility of undesired 
outcomes. In Table 5.2, we offer a list of statements commonly made by opponents of relaxing 
cannabis laws. 
TABLE 5.2 
Statements commonly made by opponents of cannabis law reform 
Crime/public safety Will not decrease, and may possibly increase, illicit market activity 
Burden on law enforcement and public safety  
Increase drug-induced crime, accidents, and negligence  
Increase in drugged driving 
Health Increase prevalence 
Increase potency, reduce price, and increase access to new products 
Entices youth and new consumers 
Increases addiction and substance use disorder 
Encourages experimentation and use of other drugs 
Normalises drug use, potentially re-normalisation of tobacco use 
Prevention Makes prevention campaigns ineffective 
Economic/budget Increases costs to state 
Reduces productivity  
Normative Sends the wrong message 
Incompatible with international treaties 
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Table 5.3 lists some potential metrics that could be used for monitoring and evaluating the impacts of 
cannabis legalisation on particular policy objectives. This list is based on the studies listed in 
Section 4 as well as our own experiences evaluating other cannabis policy changes. It also builds on 
some of the suggestions offered in Kilmer and Pacula (2017). In the table, we have placed these 
items into four general categories that are not mutually exclusive (20): health, crime and criminal 
justice, economics and other. We are not aware of any country that collects all the variables listed in 
the table, and it is likely that additional variables of importance are missing. 
TABLE 5.3 
Variables for monitoring implementation and evaluating changes in cannabis policy 
Variables Sources for obtaining these data Implications for evaluating policies 
HEALTH 
Prevalence General population surveys (GPS), 
school surveys, medical surveys 
Adult annual and 30-day prevalence rates are expected to 
increase with cannabis liberalisation; however, the health 
implications of this are unclear, as simple increases in 
prevalence rates indicate nothing about the potential health 
risks associated with consumption. More information about 
frequency of use, mode of administration and product 
consumed is needed to fully understand the potential health 
impacts of the changes in prevalence rates. 
The effect of legalisation on youth prevalence rates is 
ambiguous. The rates could increase, as we expect they will 
with adults, but they could decrease (1) if the regulated 
market makes it harder for young people to access cannabis 
and/or (2) if there is a forbidden fruit effect (MacCoun, 
1993). These effects may also offset one another. 
Frequency GPS, school surveys, medical surveys If cannabis liberalisation policies increase frequency of use 
— especially daily/near-daily use — then there are greater 
potential health effects. Specific health risks depend on the 
demographics of the user group (young people v adults, 
pregnant women or other at-risk users), the amount 
consumed per dose, the potency and the cannabinoid 
profile of the products consumed, and the method of 
ingestion — all of which will influence the actual health risk. 
Cannabis use disorder 
(CUD) 
GPS or school surveys; voluntary 
treatment, and ED and hospital 
admissions; qualitative interviews with 
selective populations — all of these 
sources capture a subset (sometimes 
overlapping) of people with CUD 
For duration, longitudinal studies 
would be strongly preferred, but it may 
be possible to get some of this 
information from retrospective 
surveys. 
The rates of CUD might rise or fall with cannabis 
liberalisation, depending on what happens to heavy use and 
treatment admissions. 
On the one hand, a decrease in criminal justice referrals 
could reduce the probability of someone with CUD receiving 
treatment. On the other hand, legalisation may make it 
easier for those with CUD to talk openly about their 
problems and obtain help. 
Products used GPS, school surveys, medical 
surveys, traceability data and 
qualitative surveys of key user groups 
There are different risks associated with different types of 
cannabis products. Some adverse health events are tied 
directly to acute overconsumption of THC, while other 
longer term health effects are related to the method of 
administration (i.e. the long-term effects of smoke on the 
respiratory system). As a result, information on the products 
used will be useful for thinking about the potential health 
consequences observable among the population.  
(20) For example, traffic accidents could be included in either health or crime.
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Variables Sources for obtaining these data Implications for evaluating policies 
Amount consumed 
 
Questions about the amount of 
cannabis consumed may be included 
in GPS or school surveys as well as 
medical surveys. Some web-based 
surveys ask about the amount 
consumed and use picture prompts to 
help guide respondents. In such 
cases, respondents are randomly 
shown a photo of different amounts of 
cannabis and asked to quantify how 
much they think each amount weighs. 
This improves researchers’ 
understanding of the amount of 
cannabis consumed. Capturing the 
potency of the product (actual or 
perceived) is also useful but may best 
be obtained through qualitative 
interviews with selective populations. 
The amount consumed per day or per episode of use is 
important for understanding (1) the risk of an acute harm 
and (2) the risk of developing a CUD. Ideally, it would be 
preferable to move beyond grams of herbal cannabis or 
puffs from a vape pen towards collecting information about 
the consumption of THC and other chemicals in the 
cannabis plant. 
Prevalence and 
consumption of other 
substances 
GPS, school surveys, medical 
surveys; treatment admissions; 
hospital and ED admissions; and 
qualitative studies of key user groups 
The net effects of cannabis liberalisation on public health 
depend on whether cannabis becomes a substitute for or 
complements other potentially harmful substances. For 
example, if cannabis is used most often with tobacco (i.e. 
they are ‘complements’), then cannabis legalisation might 
hamper efforts to reduce tobacco use. If cannabis and 
alcohol are substitutes, then having users switch from 
alcohol to cannabis might generate net health gains (e.g. 
reduced accidents, reduced domestic violence, reduced 
liver cirrhosis). If cannabis and alcohol are complements, 
then some health risks may be made worse with cannabis 
liberalisation policies (e.g. accident risk, heart risk). Thus, it 
is important to understand if liberalisation policies lead to the 
use of cannabis in lieu of other substances (tobacco, 
alcohol, opioids, new synthetic cannabinoid agonists) or to 
joint consumption. This might differ among different 
segments of the population. 
Other mental health 
disorders 
GPS, school surveys, medical 
surveys; longitudinal surveys; 
treatment admissions; hospital and ED 
admissions; qualitative studies 
involving key populations 
Even if cannabis use does not directly cause mental health 
disorders but simply increases the likelihood of onset at an 
earlier age, cannabis liberalisation policies may still increase 
the prevalence of some mental health disorders (psychoses, 
schizophrenia, etc.). The correlation may depend on the 
typical amount consumed, frequency of use and THC 
exposure. 
Treatment admissions 
 
Treatment facilities; healthcare 
systems; GPS surveys; qualitative 
studies on selective populations 
Possibly from government healthcare 
records 
If cannabis liberalisation policies lead to an increase in 
consumption such that they increase the prevalence of 
CUD, it is possible that a jurisdiction will see a rise in 
cannabis-related treatment admissions. However, if 
treatment referrals for cannabis come largely through the 
criminal justice system, then legalisation may lead to an 
overall decline in treatment admissions. 
Hospitalisations and ED 
visits 
Hospital databases; insurance claims ED visits and hospitalisations may emerge from one of three 
potential mechanisms: (1) immediate unexpected reactions 
to cannabis products consumed by naive users (e.g. 
accidental poisoning from edibles); (2) risky modes of 
consumption (e.g. dabbing) or behaviours while intoxicated 
(e.g. driving); and (3) longer term health problems 
aggravated by prolonged cannabis use, particularly in 
certain forms of products (e.g. respiratory issues from 
smoking). 
Calls to poison control 
centres 
Poison control centres; emergency 
service calls 
Calls to poison control centres typically result from 
overexposure to THC, which most frequently occurs through 
the overconsumption of edibles (multiple standardised 
doses) or exposure to high-potency products. 
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Variables Sources for obtaining these data Implications for evaluating policies 
Education and 
employment outcomes 
GPS or school surveys; longitudinal 
surveys; education and employment 
agencies; standardised testing results 
in secondary schools or for 
graduation; graduation rates; 
employee drug testing data 
Absenteeism and presenteeism are both potentially affected 
by increases in cannabis use, particularly if cannabis is 
consumed prior to or during work or school. Such behaviour 
could ultimately influence longer term productivity and tax 
revenues of the government. Tracking changes in education 
and employment outcomes before and after the adoption of 
a change in cannabis policy can help identify the need for 
additional workplace/school policies or targeted messaging 
regarding appropriate use. 
CRIME AND CRIMINAL JUSTICE 
Cannabis-related arrests 
and seizures 
Police statistics The legalisation of cannabis should generate a net decrease 
in the number of arrests and seizures, but these will not fall 
to zero for at least two reasons: (1) most jurisdictions retain 
the prohibition of use/purchases by young people and (2) 
illicit markets may persist for some time after a policy 
change. Information on arrests can provide insights into 
criminal justice savings associated with legalisation, while 
seizure data can provide some insight into profit motives for 
the illicit market to remain (e.g. specific products not 
available in the legal market, or specific populations unable 
to participate). Nevertheless, law enforcement data may be 
biased because of internal policy directives and changes in 
resources, agency capacity and citizen reports. Caution 
should be used when evaluating these data. 
Cannabis-related police-
citizen contacts 
Perhaps police databases — new 
record keeping may be required 
After legalisation, civilians could also 
track consumption in public spaces 
Enforcing new regulations adopted by a jurisdiction around 
legal cannabis will require resources, so tracking information 
on cannabis-related police contacts (including those that 
simply lead to confiscation) is important for accurately 
understanding the net budgetary impacts on crime and 
public safety resources. This information can also be useful 
for understanding how changes in cannabis laws affect 
racial/ethnic disparities in criminal justice outcomes. 
Unregulated cannabis 
processing involved in 
explosions 
Police or public safety statistics Though some individuals may already be processing illicit 
cannabis flower and turning it into concentrates, the 
legalisation of cannabis might encourage more people to 
extract cannabinoids from dried plant matter using volatile 
chemicals and solvents. Unsafe processing practices may 
pose a public safety hazard should the volatile chemicals 
combust. 
Penalties for cannabis 
offences 
Court records; corrections agencies, 
police databases 
In the US, arguments have been made that cannabis 
legalisation will improve civil liberties, reduce racial 
disparities in the criminal justice system and improve police-
community relations. Monitoring how the criminal justice 
system responds to changes in the law will allow us to 
evaluate these arguments. 
Criminal justice spending 
on enforcing cannabis 
laws 
Police databases; court records; 
corrections agencies; regulatory 
agency data (compliance checks, 
citations, fines) 
As previously stated, the enforcement of new regulations 
adopted within a jurisdiction will require some criminal 
justice resources, particularly if some violations of the new 
regime still involve criminal penalties. Tracking this 
information is necessary for understanding the cost of 
enforcing the new policy and net criminal justice savings. 
Self-reported impaired 
driving (or travelling with 
someone who is 
impaired) 
GPS, school surveys, medical 
surveys; could be added to treatment 
intake surveys 
This is one of the most likely infractions to arise in response 
to the legalisation of cannabis within a jurisdiction, although 
the rate of increase depends on a variety of factors, 
including a jurisdiction’s reliance on cars, the deterrent 
effect from law enforcement and the effectiveness of 
prevention campaigns to promote sober driving/responsible 
use. However, not all impaired driving will be detected, so, 
given limited policing resources, these data will be useful for 
understanding which groups are likely to drive under the 
influence of drugs and where and at what times such 
behaviour is likely to occur. 
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Variables Sources for obtaining these data Implications for evaluating policies 
DUI prosecutions Police statistics; insurance claim data; 
qualitative data collection in particular 
areas 
DUI arrests and prosecutions are a function of (1) the 
amount of impaired driving and (2) the level of enforcement. 
Higher DUI arrests without additional enforcement suggest a 
rise in impaired driving and the need for additional 
messages to be targeted at at-risk users. It also raises the 
criminal justice costs associated with legalisation. However, 
total DUI arrests might fall with a change in policy if 
cannabis becomes a substitute for alcohol. Thus, 
information on DUI arrests (for alcohol, cannabis and other 
substances if available) can help inform the jurisdiction 
about how cannabis is being used by specific segments of 
the population. Nevertheless, changes in enforcement 
priorities and training may confound analyses that use law 
enforcement data. 
Traffic crashes or 
fatalities 
Transport and insurance claims 
databases 
Changes in traffic crashes and fatalities may indicate a 
change in impaired driving that is not reflected in arrest 
statistics. Objective analyses will focus on the total number 
of crashes/fatalities, not just those in which the driver tested 
positive for THC. This can offer a better understanding 
regarding the potential substitution of cannabis for alcohol or 
their concurrent use. 
Arrests/convictions for 
other crimes 
Police databases; court records Tracking changes in arrests/convictions for other crimes 
helps to identify the public safety benefits/costs associated 
with legalisation — in so far as arrests reflect changes in 
crime patterns (that may be associated with use of cannabis 
and/or its substitutes or complements). Nevertheless, 
changes in enforcement priorities and training may 
confound analyses that use law enforcement data. 
Calls to emergency 
services 
Police databases, possibly other 
government agencies 
Since not all crimes result in an arrest, tracking information 
from calls to emergency services may identify changes in 
the need for law enforcement intervention because of a 
change in the consumption of cannabis and/or its 
substitutes and complements. 
Victimisation surveys Victimisation surveys; medical reports Information on the changes in victimisation with the 
legalisation of cannabis is relevant for considering public 
safety impacts. Again, it is unclear if victimisation would rise 
or decline with legalisation; much will depend on how the 
policy change affects the use of other substances.  
ECONOMICS   
Total expenditures on 
purchasing cannabis 
products 
GPS; retail sales (medical or other 
outlets); combining consumption 
estimates from wastewater testing with 
THC price estimates  
Information on cannabis expenditure serves at least three 
purposes: (1) it helps identify tax evasion, particularly if 
taxes are tied to the amount sold; (2) it is helpful for 
understanding which products are sold (by form and 
potency if information is collected by product); and (3) it is 
useful for constructing an estimate of the total size of the 
cannabis market (demand based), which can then be used 
as a way of measuring the impact of further policy 
refinements on the market. 
Source of cannabis 
supply 
GPS; web surveys of heavy users Information on the source of cannabis is very helpful for 
understanding the extent to which the legal market is able to 
replace the illicit market. 
Amount of cannabis 
produced in the legal 
market  
Traceability systems; visual 
inspections 
Traceability systems are valuable for a range of regulatory 
purposes in a legal cannabis market, including (1) 
measuring the total amount supplied to a market (which, 
when combined with a demand estimate, can identify the 
presence and size of an illicit market); (2) projecting 
estimates of tax revenue from sales (which can then be 
compared with actual tax revenue to help identify tax 
evasion); and (3) identifying and tracking products sold, 
which is useful for understanding the potential health risks 
that consumers might face (this is relevant to prevention 
messaging as well as the issuing of product recalls).  
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Variables Sources for obtaining these data Implications for evaluating policies 
Prices GPS, medical surveys, arrestee 
surveys; web surveys of heavy users; 
menu analyses; traceability systems; 
law enforcement sources; 
crowdsourcing websites such as ‘Price 
of Weed’ 
Prices are important, because they can influence many of 
the outcomes that are discussed in cannabis policy debates: 
size of the illicit market, tax receipts, business revenues and 
consumption. 
Presence of retail 
establishments 
Regulatory agency overseeing 
cannabis legalisation; local 
government zoning boards 
The illicit market for cannabis can be reduced if there is a 
licensing system identifying legitimate sellers from illegal 
sellers. Enforcement against illegal sellers is a necessary 
component of a licensed system. However, the density of 
retail establishments can also influence the perceived 
availability (changing norms about the substance) and can 
reduce the effectiveness of prevention programmes aimed 
at reducing use among particular groups. The regulation of 
retail establishments will be a cost of legalisation, affecting 
net revenues from a change in policy. More retail 
establishments increase the number of entities that need to 
be policed (and hence the cost of doing so). 
Licit sales and tax 
revenues 
Regulatory agency overseeing 
cannabis legalisation; other 
government agencies 
Tracking sales and tax revenue is important for measuring 
the size of the market and whether or not tax revenue is 
growing. These taxes are often earmarked for prevention 
efforts, regulatory oversight and other costs imposed by 
users on society. 
Employment in the 
cannabis industry and 
other related industries 
Could try to deduce this from total 
production estimates and qualitative 
methods pre legalisation; after 
legalisation, it should be part of regular 
labour statistics 
Information on employment in the cannabis industry can 
indicate the economic value of the industry to a community. 
It also provides insights into the relative importance of this 
industry vis-à-vis other industries in an area. 
Of course, legalisation can affect other segments of the 
economy, besides those directly involved in the cannabis 
trade. 
Cost of regulation and 
law enforcement 
Regulatory agencies overseeing 
cannabis legalisation; police 
databases; court records; corrections 
While there are likely to be criminal justice savings 
associated with cannabis legalisation, there are also agency 
costs associated with regulating a new business. The 
economic impact of legalisation is a function of the jobs and 
tax revenue that comes with the new market minus the cost 
of regulation and law enforcement monitoring and regulating 
the new market. This information is vital for a proper 
estimation of the net economic impact of legalisation. 
OTHERS 
Consumer characteristics Administrative or regulatory data; 
qualitative studies of key target 
populations 
Jurisdictions that collect information on patients or 
registered adults (e.g. Uruguay) may allow for a further 
understanding of the user base. This could include 
descriptive information on patient ailments or demographic 
information regarding a typical registrant and how much 
they purchase over the course of a year. 
Public support Public opinion polls These polls provide a source for evaluating the normative 
justification for a change in cannabis policy. 
Advertising/promotion Could require all cannabis 
advertisements be reported to 
regulatory agencies; could also 
conduct studies by the European 
Medicines Agency 
The degree to which cannabis products are advertised and 
promoted might influence the type and amount of prevention 
material needed by a community to reduce the potential 
harms associated with legalisation. 
5.2 Establishing the data infrastructure 
Once a jurisdiction has identified the objectives for considering a policy change as well as specific 
metrics that would be useful for monitoring impacts, it can then consider appropriate data collection. 
The second column of Table 5.3 offers ideas for collecting or generating relevant data. Keep in mind 
that there are strengths and weaknesses of different data sources and various approaches. In this 
section, we discuss in greater detail some of the issues to consider when relying on some of these 
sources. 
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General population surveys (GPS) and student surveys 
GPS and student surveys will be useful for some of these items, but care must be taken when using 
these data to draw inferences about cannabis policy changes, for several reasons. Most importantly, 
there is strong evidence suggesting that survey respondents under-report the prevalence of drug use 
in GPS (e.g. Harrison et al., 2007). While many studies have relied on assumptions that under-
reporting — although unknown — is fairly stable year on year, these assumptions will not necessarily 
hold if a policy changes. For example, if a policy change reduces the stigma around admitting 
cannabis use, then more people will be willing to honestly report their prior behaviour, making it hard 
to identify the extent to which any change detected is attributable to a true increase in cannabis use 
as opposed to more honest reporting, or both. 
One way to assess the degree to which under-reporting might exist and change with policy would be 
to validate the GPS with a biological test (e.g. saliva tests or urinalysis), to determine the proportion of 
respondents who are misreporting at a given point in time. This has been done in the US, but we are 
not aware of any attempts to do this in Europe (Kilmer et al., 2015). Another alternative that might be 
considered is to incorporate the use of the randomised response technique for key estimates into the 
questionnaires (Blair et al., 2015). Such validation does not have to be done every year, but doing it 
now and possibly a few years after a significant policy change would provide extremely useful 
information about baseline rates of under-reporting and how these change over time. The use of 
wastewater epidemiology may potentially generate useful confirmatory measures for cannabis 
prevalence rates (Zuccato et al., 2008). Countries in Europe and elsewhere may not want to rely on 
US under-reporting estimates from nearly 20 years ago to inform these adjustments. 
There are also some questions that could be added to GPS regarding consumption and expenditure 
that would improve our understanding of these markets and how they could change (e.g. asking about 
the types of cannabis products used and the amount consumed). Adding questions about market 
transactions is critical for understanding expenditures and revenues generated by illicit suppliers, 
which is important if the goal is to understand the impact of policy changes on the size of the illicit 
market. Since it may not be possible to add an entire cannabis market module, as was done in the US 
from 2002 to 2014 (and reinstated in 2018), adding two questions concerning (1) the amount spent 
during the last purchase and (2) the number of purchases in the previous month would be enough to 
provide the foundation for market estimates. 
It would also be helpful to collect information about the types of products purchased. Information on 
the types of products is especially valuable if a jurisdiction decides to limit the legal sale of cannabis 
to particular forms (e.g. herbal cannabis), which Uruguay does. Responses can indicate if individuals 
are sourcing other products (e.g. edibles) from illicit markets. 
Web surveys  
While it is possible to use internet-based surveys with strong sampling frames to generate population-
representative inferences about cannabis use and purchasing patterns (e.g. Pacula et al., 2016), 
many of the web surveys about cannabis fielded in Europe and the US are convenience samples (e.g. 
Kilmer et al., 2013; van Laar et al., 2013; Matias et al., 2019). While these relatively inexpensive 
surveys do not allow for precise estimates about a representative sample, they can provide plausible 
ranges for key variables if the samples are large enough. If targeted correctly, they can help provide 
information about heavy users, who may be less likely to be included in the sampling frame for GPS 
or student surveys but account for the largest part of consumption and expenditures (Kilmer et al., 
2014). 
Indeed, combining estimates from GPS and web surveys is becoming an increasingly popular 
approach to generating market estimates for consumption and expenditures. Typically, the GPS 
estimates of the number of use days are combined with the web survey estimates of the amount 
consumed per use day for various types of users (e.g. weekly, daily/near daily). In some cases, these 
estimates are generated only for an entire country (e.g. Caulkins and Kilmer, 2013), while other 
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studies generate these estimates for specific age or gender groups and then add them together to 
generate an aggregate estimate (e.g. Caulkins et al., under review; van Laar et al., 2013). Another 
approach to using unrepresentative web surveys to generate population-wide estimates is to use a 
raking algorithm to reweight web survey respondents to match GPS data (see Caulkins et al., 2019). 
Cannabis medical surveys  
In the light of the changes happening within US jurisdictions, several health insurers are beginning to 
elicit information about cannabis use (both medicinal and recreational) in their regular patient surveys 
so as to monitor use of the substance in a fashion similar to alcohol and tobacco. While this 
information is not publicly available from private insurers, it could easily be collected by public insurers 
in various jurisdictions. Distinguishing medicinal consumption from recreational consumption would be 
key, as the particular forms of cannabis, the amounts consumed and frequency of use are likely to 
differ, depending on the subpopulation considered (Pacula et al., 2016; Lankenau et al., 2017). 
Cannabis tracking systems  
In the shadow of federal prohibition, states that passed legalisation have implemented ‘seed-to-sale’ 
traceability systems to signal that they are taking the issue of diversion seriously. These systems track 
every plant throughout the supply chain, ending at retail sale. They can include information about the 
prices paid by processors and retailers as well as information about cannabinoid content and the 
types of products sold on the licit market. While these systems were not necessarily designed for 
research purposes, they are being used by an increasing number of researchers to help understand 
the markets and other cannabis-derived products (Smart et al., 2017), to estimate the price elasticity 
of demand (Hansen et al., 2017) and the level of competition in the market at the wholesale and retail 
levels (Caulkins et al., 2018). 
In the US, there are no systems to track sales made to specific individuals (i.e. the identities of 
purchasers is not tracked), but there are in Uruguay. In addition to a seed-to-sale system, Uruguay 
tracks and limits purchases by individuals. Retail purchases can be made only at participating 
pharmacies and are limited at 40 g/person/month. To make sure individuals do not exceed these 
limits, a biometric system requires registered buyers to submit a thumbprint before making a purchase 
(Miroff, 2017). The pharmacy receives immediate feedback from the government database about 
whether or not the person has exceeded the allowable retail transaction limit; if not, the sale is made. 
The total weights and numbers of sales per location are then reported to the national monitoring 
agency. 
Other countries considering changes in cannabis policy are not constrained in the same way as the 
states in the US, and may want to limit the amount of cannabis that can be purchased in a given time 
period, or consider implementing seed-to-sale systems to obtain data that are relevant to other policy 
objectives, including identifying leakages to the illicit market, contaminated products for recalls and 
valuable information regarding the types (and amount) of various products sold. This information can 
be important for monitoring compliance and providing information for economic and other analyses. 
Such information will allow regulators and researchers to triangulate with other indicators, such as 
self-reported user behaviours from population surveys. 
5.3 Thinking seriously about outcome evaluations 
The third column of Table 5.3 provides an explanation for why particular types of data are useful for 
generating inputs that can be used to measure many outcomes of interest, including (1) the actual 
demand for cannabis in a market; (2) the size of the legal cannabis supply and industry; (3) the size of 
the illicit market supply of cannabis; (4) the net impact of cannabis legalisation on the criminal justice 
system (arrests), the public safety system (calls to emergency services, victimisation) and the health 
system (hospitals, poison control centre calls, accidents); and (5) the net economic impact of the 
market on the government in terms of jobs created, tax revenue, regulatory costs and health/law 
enforcement net costs (or savings). It is worth mentioning that this report and many evaluations of 
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REC to date exclude any evaluation of the benefits — including mere pleasure — of legal cannabis 
reforms. It is difficult to assess these consequences, as they are often subjective and difficult to 
quantify, but any serious evaluation of these legal changes ought to consider these outcomes 
(Caulkins et al., 2016). 
Collecting the appropriate outcome data is necessary but insufficient for evaluating these policy 
changes. Serious thought must be given to defining precisely what is evaluated and what is the 
counterfactual, to allow the determination of causal inference about policy change. This section 
addresses some of the issues for those considering an evaluation. 
Understanding the cannabis market and expected sanction for a cannabis violation before the 
policy change 
There are a number of mechanisms that may influence cannabis use after a policy change, such as 
stigma, price, promotion, availability, expected sanction and the ‘forbidden fruit’ effect (MacCoun, 
1993). Collecting the baseline data for price and expected sanction is important for understanding not 
only the casual mechanisms at play but also how different forms of legalisation may have different 
effects on use and other outcomes. For example, if a jurisdiction that does not criminally sanction 
cannabis possession chooses to legalise the supply of cannabis, the criminal justice cost savings of 
doing so will not be as great as a jurisdiction that criminally sanctions cannabis users. Alternatively, if 
a government implements a regulatory regime that keeps the price per unit of THC similar to its pre-
legalisation price, it may not detect as much of an effect on use compared with other regimes that 
have experienced price declines as a result of market competition (Kilmer et al., 2010). 
Collecting market information (e.g. information on prices, products, promotion, the number of outlets) 
is important, especially for jurisdictions that had vibrant commercial medical markets before 
recreational legalisation. It could also be useful in countries such as Spain, where, despite national 
prohibition, significant numbers of cannabis social clubs are tolerated in some regions, some of which 
may become increasingly commercialised (Pardal, 2018). 
Canada has made an effort to obtain baseline data for future evaluations. For example, building on 
the Canadian Student Tobacco, Alcohol and Drugs Survey, Health Canada designed the Canadian 
Cannabis Survey, aimed at understanding the pre-legalisation cannabis market. In 2017, the national 
government fielded the phone-initiated survey designed to obtain a sufficient representation among 
key population groups across all provinces and territories. The survey not only included questions that 
are relevant to cannabis consumption but asked respondents about their purchasing habits (how 
much they bought, how often, from what sources and at what prices). The findings informed 
discussions on the cannabis law and will also be used to evaluate its implementation in the future 
(examining changes in prevalence, price, frequency of use, etc.). In addition, Public Safety Canada 
commissioned work to estimate the price of cannabis throughout the country (Ouellet et al., 2017), 
and Statistics Canada created a ‘Cannabis Stats Hub’, which has many similarities to the EMCDDA’s 
Statistical Bulletin but includes more detailed information about the cannabis economy. 
Considering the counterfactual and underlying context  
Section 4 highlights the growing number of studies recreational legalisation in the US that include a 
control group, but much attention is still paid to simple pre-post analyses of trend data (for more on 
trends, see Appendix C). While cross-jurisdictional comparisons seem like an obvious approach to 
applying rigorous research methods to learn about these policy changes, caution must be exercised, 
as important differences in definitions, survey methodologies, the frequency of data collection and 
other factors can limit inferences from these exercises (MacCoun, 1993; Kilmer et al., 2015; 
Giommoni et al., 2017). More importantly, the assumption that any single jurisdiction adopts a uniform 
policy, which is required and embedded in many cross-national studies, is clearly problematic (e.g. 
states in the US vary considerably in terms of their cannabis regulations and enforcement). Similarly, 
context matters. Different jurisdictions may have different starting points for the adoption of REC. This 
may be less of a transition for a jurisdiction with a robust medical cannabis market or some social 
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access (e.g. the Dutch coffee shops or cannabis social clubs in Spain) than for a jurisdiction that 
aggressively enforces cannabis prohibition. 
Another approach is to take advantage of within-state variation in how policy is being implemented. 
For example, although the states of Colorado and Washington passed legalisation in 2012, there are 
still a number of localities in these states that do not allow retail stores. This has allowed researchers 
to exploit the variations in retail cannabis outlet density to learn more about the effect of 
commercialisation (e.g. Dilley et al., 2017). Similarly, studies exploiting variations in medical cannabis 
access within California have been carried out to examine the impacts on use, hospitalisation and 
crime (e.g. Mair et al., 2015; Freisthler et al., 2016; Hunt et al., 2018). An advantage of using intra-
state variation is that there is less concern about data comparability and policy comparability, and 
there may be shorter time lags. Of course, there may be important issues of policy endogeneity that 
will need to be considered in the statistical models (Pacula and Smart, 2017). 
Paying close attention to dates and isolating policy exposure 
The date used to denote when the policy change occurred obviously has important implications for 
the results of outcome analyses. There can be not only lags between the date of passage and the 
date the policy goes into effect but also important lags between passage and the ability to purchase 
cannabis from a store, as it can take time to build a regulatory system. For example, the voters in 
Colorado and Washington passed legalisation in November 2012, but the recreational stores did not 
open until January 2014 and July 2014, respectively (21). Thus, outcome analyses of legalisation that 
use dates when laws were passed, rather than when stores opened (or when a majority of the adult 
population had access to cannabis), are at serious risk of drawing the wrong conclusions if changes 
are driven principally by market activity and not shifts in norms (Pacula and Smart, 2017). The dates 
can also be useful for learning more about the causal mechanisms underlying possible changes in 
use (e.g. the period when it is legal to use or possess but before the stores have opened) and 
understanding the short- and long-term implications of these policies. 
It is imperative that when regulatory changes are introduced, governments, or possibly agencies such 
as the EMCDDA, document what the legal changes allow/require and whether or not local variation is 
permitted (e.g. if shops allowed). Although this seems obvious, it can be difficult to obtain this 
information, as enacted laws may not include regulatory details that can influence outcomes of 
interest (e.g. testing requirements). Better-prepared jurisdictions will require regulatory agencies to 
publicly document this information and note when changes are made to regulations. This type of 
documentation is especially important if the new policy allows local variation. 
Acknowledging that the short- and long-term effects of legalisation could be different  
It is entirely possible that the short-term effects of a policy change differ from the long-term effects. 
This is likely to be true, as knowledge about products and how they might be used (or misused) takes 
time to develop, as do changes in social norms concerning the appropriate (or inappropriate) use of 
the products. Even existing markets can see the introduction of new products (e.g. hash oils and 
concentrates) that capture different properties of the original cannabis plant (e.g. higher THC content) 
and which can also change the known health impacts of the substance. It is certainly the case that we 
have very little knowledge of the health implications of the products currently sold in US legal markets 
(e.g. Kilmer, 2018). Most of the research on the health benefits and consequences of cannabis are 
based on cannabis plant material with far lower THC and higher CBD concentration levels than those 
observed on the legal market in the US today. Thus, it is difficult to infer the long-term effects of these 
newer, less researched, products. 
(21) Even though some stores opened in Washington in July 2014, it was some time before most of the licensed stores opened
and had enough inventory to push prices below the pre-legalisation levels.
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6. Concluding thoughts
This document is intended to inform discussions about the value of having tools in place to evaluate 
the impact of any major changes to the regulatory approach to cannabis used. By highlighting the 
various approaches unfolding in the Americas and some of the emerging evidence from states in the 
US, namely Colorado and Washington, we construct an analytic framework and empirical foundation 
that we hope will contribute to productive and dispassionate policy discussions. 
We cannot stress enough that the peer-reviewed literature review on legalisation of adult cannabis 
use is nascent, and that results are likely to be conflicting, depending on which data and methods are 
used as well as which policies are evaluated. It is important to remain sceptical of early studies, 
especially those that use a simple binary variable to classify legalisation and non-legalisation states. 
This scepticism should extend to the many studies that fail to account for the existence of robust 
commercial medical cannabis markets that predate recreational cannabis laws. Even if a consensus 
develops on certain outcomes, this does not mean that that relationship will hold over time. Changes 
in norms concerning cannabis use and potentially other substances, the maturation of markets and 
the power of private businesses (if allowed) could lead to very different outcomes 15 or 25 years after 
recreational cannabis laws have been passed. Evaluations of these changes must be considered an 
ongoing exercise, not something that should happen in the short term. 
Insights from evaluations of possible supply changes in Europe will depend on the number of data 
collected before the change; simply comparing past-month prevalence rates will not tell us much 
about the effect of the change on health. While US jurisdictions have been moving quickly to legalise 
cannabis, the data infrastructure for evaluating these changes is limited. In contrast, Canada has 
made important efforts to field new surveys and create new data collection programmes in 
anticipation of legal changes. If some jurisdictions are considering a major adjustment to cannabis 
supply policies in the near future, then it is prudent to start thinking as soon as possible about 
improving data collection and analysis systems to support subsequent evaluation exercises. Given 
the open borders that exist within the EU, the wider impact of policy changes made within any one 
country will also deserve consideration. Section 5 of this report should serve as a useful resource for 
some of these discussions. 
While there is much to learn from what is happening in the Americas, policy discussions should not be 
limited to approaches implemented there. There are several regulatory tools (e.g. minimum pricing, 
potency-based taxes) that receive very little attention — if any — that could have important 
consequences for health, public safety and/or social equity (22). Acknowledging that individuals (and 
governments) have different values and preferences for risk when it comes to cannabis policy can 
make for more productive discussions on this controversial topic. 
(22) Uruguay is one exception here. The government does not set a minimum price for cannabis sold in the pharmacies — it
sets the price. Some provinces in Canada are contemplating THC potency taxes, while others have the authority to set a price
floor.
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Appendix A: Identification and commentary on ongoing/planned 
studies of legalisation 
Here, we identify some ongoing or planned studies from the US, Uruguay and Canada that examine 
the impacts of cannabis policy changes. This is not a comprehensive list; the goal is to highlight the 
variety of studies being conducted, to learn more about cannabis and the consequences of various 
policy changes. 
US studies 
Studies funded by the National Institutes of Health (NIH) 
The NIH, largely through the National Institute on Drug Abuse (NIDA), has supported a broad portfolio 
of research on cannabinoids and their use in the endocannabinoid system (23). This includes funding 
ongoing research into the use of phytocannabinoids, purified cannabinoids, such as CBD and THC, 
and synthetic cannabinoids. In FY 2017, the NIH funded research into cannabinoids to the value of 
USD 140 million through various research arms, including NIDA (USD 88 million) and the National 
Institute on Alcohol Abuse and Alcoholism (NIAAA) (USD 21 million). In addition, the NIH provided an 
additional USD 36 million for research into therapeutic cannabinoids, allocating USD 16 million to 
NIDA and USD 6.5 million to the National Institute on Alcohol Abuse and Alcoholism (NIAAA). The 
NIH also provided an additional USD 15 million for research into CBD, USD 11 million of which went 
to NIDA. 
NIDA is currently undertaking several studies that are specific to cannabis use and the impacts of 
legalisation. The most ambitious study is the Longitudinal Study of Adolescent Brain Cognitive 
Development (the ABCD study), which aims to enrol almost 12 000 healthy children aged 9 and 10 
years (singletons and twins) across the US and follow them into early adulthood. According to NIDA, 
this is the largest long-term study of brain development and child health in the US. 
The study, which is being carried out in partnership with the NIAAA, will examine how biology and 
environmental factors relate to developmental and physical outcomes, including mental health and life 
achievements. Researchers will employ brain imaging technology to evaluate changes over time. 
Specific to cannabis legalisation, the study will examine the impact of the changing state and local 
policies on youth drug use and related development. For example, it will examine the extent to which 
casual or regular use of cannabis during adolescence has an impact on neurodevelopment in 
adulthood. 
The study is still currently enrolling participants. Since September 2016, researchers have enrolled 
just over 10 000 participants. Baseline data obtained from the first 4 500 participants, suggest that 
drug use among participants is minimal. 
One active study by NIDA is looking at medical cannabis use among primary care patients in states 
with legal medical and recreational cannabis laws. The aims of the Medical Cannabis Use among 
Primary Care Patients study are to better understand the medical use of cannabis in a single, large 
health system that asks patients about their cannabis use and to describe their cannabis use 
behaviours and compare them with others who use cannabis without medical recommendations. 
Studies funded by the National Institute of Justice (NIJ) 
The NIJ is currently funding multiple studies that examine the impacts of cannabis in the US, including 
                                                     
(23) See https://www.drugabuse.gov/drugs-abuse/marijuana/nih-research-marijuana-cannabinoids 
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one study examining the effects of Colorado’s REC law on DUIs and crime (24). The NIJ has also 
funded a USD 1 million study on the impacts of marijuana legislation on law enforcement and crime in 
Washington state. 
Studies funded by US states 
Colorado (25) state has granted USD 9 million of public funds to cannabis research, dispersing the 
funds across nine studies. The studies focus on the health benefits of using medical cannabis to treat 
inflammatory bowel syndrome, Parkinson’s disease, epilepsy (two studies), post-traumatic stress 
disorder (PTSD) (two studies), palliative care, insomnia and pain relief. The state has also funded 
USD 2.4 million of research into the public health effects of REC, focusing on driving impairment, the 
acute effects of dabbing (26), the concentration of cannabinoids in breast milk, use in older 
populations, the adverse effects of edibles, cardiovascular effects and a general pre/post analysis of 
broad public health impacts. 
Under Washington (27) state’s initiative, a portion of cannabis tax revenue is earmarked for research. 
For the period 2015-17, the Alcohol and Drug Abuse Institute of the University of Washington 
received USD 454 000 from the state’s Dedicated Marijuana Fund. Current and ongoing research 
focuses on areas of epidemiology, chronic pain management, impacts on driving and the efficacy of 
innovative prevention programmes. 
Uruguay 
There are two ongoing academic monitoring and evaluation groups. The first is the Monitor Cannabis 
Uruguay group, affiliated with the School of Social Science at the University of the Republic of 
Uruguay. Monitor Cannabis Uruguay researches ongoing developments related to cannabis in the 
country. Current ongoing research focuses on the impact of the law on security. The second 
academic group is housed at the Catholic University of Uruguay, which maintains the Latin American 
Marijuana Research Initiative (LAMRI) (28). LAMRI is funded by the Open Society Institute (a non-
governmental organisation that advocates drug policy reform) and evaluates ongoing cannabis policy 
trends in Uruguay and the rest of the region. LAMRI-affiliated researchers have published papers on 
consumption patterns, cannabis user opinions and cannabis club design in Uruguay. 
The Uruguayan Drug Observatory published a preliminary study (29) in 2015 on drug use among 
university students to evaluate their opinions, prevalence and source of cannabis. Though the law had 
not been fully implemented, researchers included questions on home cultivation. 
Canada 
The Canadian government (30), through the Canadian Institute of Health Research, has allocated 
CAD 1.4 million to study the effects of cannabis legalisation on certain groups and evaluate existing 
regulatory models. Funds are to be distributed across 14 studies led by universities and hospitals, 
looking at youth prevention, exposure in pregnancy, impaired driving, trajectories of cannabis use, 
outcomes related to opioid use, cannabis use in the workplace, cannabis use in secondary schools, 
monitoring mental health outcomes and provincial responses to federal legalisation. More recently, 
Health Canada released tenders that focused on studies of cryptomarket cannabis sales and public 
attitudes. 
                                                     
(24) See https://www.nij.gov/topics/drugs/Pages/research-projects.aspx 
(25) See https://www.colorado.gov/pacific/cdphe/marijuana-research  
(26) Dabbing is the action or practice of inhaling small quantities of a concentrated and vaporized drug, typically cannabis oil or 
resin. 
(27) See http://learnaboutmarijuanawa.org/research.htm 
(28) See https://ucu.edu.uy/es/lamri 
(29) See http://www.cicad.oas.org/oid/pubs/UniversityStudyReport_Uruguay_SPA.pdf   
(30) https://www.canada.ca/en/institutes-health-research/news/2018/01/cannabis_and_populationhealthresearch.html  
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Appendix B: Research papers on the impacts of recreational cannabis laws 
Shading indicates presence in text. 
Reference Location and 
years evaluated 
Control measures Outcome Independent 
variable(s) 
REC-specific 
policy change 
Data and methods Findings 
Peer-reviewed articles 
Aydelotte et 
al. (2017) 
Washington and 
Colorado 
2009-15 
States with similar 
traffic and roadways: 
Alabama, Indiana, 
Kentucky, Missouri, 
South Carolina, 
Tennessee, Texas 
and Wisconsin 
Motor vehicle 
crash fatality 
REC REC adoption Annual number of motor 
vehicle fatalities reported in 
the Fatality Analysis 
Reporting System; 
difference-in-difference 
approach; random effects 
Pre recreational marijuana legalisation, 
annual changes in motor vehicle crash 
fatality rates for Washington and Colorado 
were similar to those for the control states. 
Post recreational marijuana legalisation, 
changes in motor vehicle crash fatality 
rates for Washington and Colorado also did 
not significantly differ from those for the 
control states (adjusted difference-in-
difference coefficient =  +0.2 fatalities/billion 
vehicle miles travelled; 95 % CI −0.4 to 
+0.9). 
Aydelotte et 
al. (2019) 
Washington and 
Colorado 
2007-17 
Hawaii, Montana, 
New Mexico, Rhode 
Island, Vermont, 
Idaho, Kansas, 
Nebraska, South 
Dakota 
Monthly motor 
vehicle crash 
fatality 
REC REC 
implementation 
(i.e., when 
stores opened) 
Annual number of motor 
vehicle fatalities reported in 
the Fatality Analysis 
Reporting System; 
difference-in-difference 
approach; random effects 
In the five years after legalisation, fatal 
crash rates increased more in Colorado 
and Washington than would be expected 
had they continued to parallel crash rates in 
the control states (+1.2 crashes/billion 
vehicle miles travelled, CI: -0.6 to 2.1, 
p = 0.087), but not significantly so. The 
effect was more pronounced and 
statistically significant after the opening of 
commercial dispensaries (+1.8 
crashes/billion vehicle miles travelled, CI: 
+0.4 to +3.7, p = 0.020). 
Anderson et 
al. (2019) 
States with MED 
or REC laws 
States without MED 
or REC laws 
Past-month 
prevalence 
rates 
MED or REC  MED or REC 
adoption 
Past-month prevalence rates 
for US high school students 
from the Youth Risk 
Behavioral Survey. 
Multivariate logistic 
regression for reporting 
past-month use. 
MED laws not associated with any reported 
changes in cannabis use. REC laws were 
associated with an 8 % decrease (OR, 
0.92; 95 % CI, 0.87-0.96). 
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Reference Location and 
years evaluated 
Control measures Outcome Independent 
variable(s) 
REC-specific 
policy change 
Data and methods Findings 
Bell et al. 
(2015) 
Colorado 
January 2008-
August 2014 
Pre/post Burns MED 
REC 
Pre REC to 
MED/REC 
enactment and 
implementation 
Cross-sectional analysis of 
American Burn Association’s 
National Burn Repository for 
hydrocarbon burns 
Twenty-nine patients with butane hash oil 
burns were admitted to the local burn 
centre during the study period. No cases 
presented prior to medical liberalisation, 19 
(61.3 %) presented during medical 
liberalisation (October 2009 to December 
2013) and 12 presented (38.7 %) in 2014, 
after legalisation. The majority of patients 
were Caucasian (72.4 %) and male 
(89.7 %). The median age was 26 years 
(range 15-58 years). The median total body 
surface area covered by burns was 10 % 
(range 1-90 %). The median length of 
hospital admission was 10 days. 
Bierut et al. 
(2017) 
Washington and 
Colorado 
June-July 2015 
None Cannabis 
advertising 
online 
REC None Cross-sectional sample of 
licensed retailers that 
advertise through 
Weedmaps (n = 146; 89 
from Colorado, 57 from 
Washington); social media 
followers of Weedmaps 
(Twitter = 57 752; 
Instagram = 2 249); 
descriptive analysis and 
non-parametric hypothesis 
testing (chi-squared test) 
Many retailers had no security measure to 
determine age (41 % in Colorado; 35 % in 
Washington). Approximately 61 % of 
retailers in Colorado and 44 % in 
Washington made health claims about the 
benefits of marijuana, including reduction in 
anxiety, depression, insomnia and 
pain/inflammation. Inferred demographic 
characteristics of followers of Weedmaps 
on Twitter and Instagram revealed that over 
60 % were male and nearly 70 % or more 
were aged 20-29 years, yet some (15-
18 %) were under the age of 20. 
Borodovsky et 
al. (2017) 
REC states 
29 April 2016 to 
18 May 2016 
Non-REC states Youth use of 
cannabis, 
including ever  
vaping or ever 
using edibles 
REC, 
operational 
dispensary, 
home 
cultivation 
Point in time Cross-sectional sample of 
cannabis-using young 
people (14 to 18 years; 
n = 2 630) surveyed online; 
logistic and linear regression 
Longer REC duration (Odds ratio (OR) 
vaping: 2.82, 95 % CI 2.24 to 3.55; OR 
edibles: 3.82, 95 % CI 2.96 to 4.94) and a 
higher dispensary density (OR vaping: 
2.68, 95 % CI 2.12 to 3.38; OR edibles: 
3.31, 95 % CI 2.56 to 4.26) were related to 
a higher likelihood of trying vaping and 
edibles. Permitting home cultivation was 
related to a higher likelihood (OR 1.93, 
95 % CI 1.50 to 2.48) and younger age at 
onset (β −0.30, 95 % CI −0.45 to −0.15) of 
consuming edibles. 
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Control measures Outcome Independent 
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REC-specific 
policy change 
Data and methods Findings 
Cerdá et al. 
(2017) 
Washington and 
Colorado 
2010-12 and 
2013-15 
Non-REC states Adolescent 
past-month 
marijuana 
prevalence of 
use and 
perception 
REC Pre REC to REC 
enactment and 
implementation 
Repeated cross-sectional 
MTF surveys (n = 253 902); 
difference-in-difference 
approach to estimate 
perception/use  
In Washington, perceived harmfulness 
declined by 14.2 % and 16.1 % among 8th 
and 10th graders, respectively, while 
marijuana use increased by 2.0 % and 
4.1 % during the periods 2010-12 and 
2013-15, respectively. In contrast, among 
states that did not legalise REC, perceived 
harmfulness decreased by 4.9 % and 7.2 % 
among 8th and 10th graders, respectively, 
and marijuana use decreased by 1.3 % and 
0.9 % over the same periods. Difference-in-
difference estimates comparing 
Washington with states that did not legalise 
REC indicated that these differences were 
significant for perceived harmfulness (8th 
graders −9.3 % (SD 3.5 %), p = 0.01; 10th 
graders −9.0 %  (SD 3.8 %), p = 0.02) and 
marijuana use (8th graders: % [SD], 5.0 
[1.9]; p = 0.03; 10th graders 3.2 % (SD 
1.5 %), p = 0.007). No significant 
differences were found regarding perceived 
harmfulness or marijuana use among 12th 
graders in Washington or for any of the 
three grades in Colorado. 
Cerdá et al. 
(2019) 
Washington, 
Colorado, Oregon 
and Alaska 
2008 to 2016 
Non-REC states Adolescent 
past-month 
marijuana 
prevalence of 
use and self-
reported 
cannabis use 
disorder 
REC 3-level variable 
determining 
never passed 
REC; before 
REC enactment, 
after REC 
enactment 
Repeated cross-sectional 
NSDUH surveys; difference-
in-difference approach  
Among respondents aged 12 to 17 years, 
past-year CUD increased from 2.18 % to 
2.72 % after REC enactment, a 25 % 
higher increase than that for the same age 
group in states that did not enact REC 
(odds ratio [OR], 1.25; 95 % CI, 1.01-1.55). 
Unmeasured confounders would need to 
be more prevalent in REC states and 
increase the risk of cannabis use by 1.08 to 
1.11 times to explain observed results, 
indicating results that are sensitive to 
omitted variables. No associations were 
found among the respondents aged 18 to 
25 years. Among respondents 26 years or 
older, past-month marijuana use after REC 
enactment increased from 5.65 % to 
7.10 % (OR, 1.28; 95 % CI, 1.16-1.40), 
past-month frequent use from 2.13 % to 
2.62 % (OR, 1.24; 95 % CI, 1.08-1.41), and 
past-year CUD from 0.90 % to 1.23 % (OR, 
1.36; 95 % CI, 1.08-1.71). 
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Control measures Outcome Independent 
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REC-specific 
policy change 
Data and methods Findings 
Cheng et al. 
(2018) 
Colorado localities 
January 2010-
August 2015 
 Housing 
values 
REC  Difference-in-difference 
ordinary least squares 
estimation 
Legalisation leads to an average 6 % 
increase in housing values, indicating that 
the capitalised benefits outweigh the costs. 
In addition, we find suggestive evidence 
that this relatively large housing value 
appreciation is probably because REC has 
induced strong housing demand while 
having no discernible effect on housing 
supply. Finally, authors show that the effect 
of REC is heterogeneous across locations 
and property types. 
Cohn et al. 
(2017) 
US 
October 2014 
None Young adult 
opinion for 
REC 
Demographic Point in time Nationally representative 
cross-sectional sample of 
adults aged 18-34 years 
from the Truth Initiative 
Young Adult Cohort survey 
(n = 3 532); multinomial 
logistic regression 
Weighted estimates showed that 39 % of 
the full sample and 9 % of non-marijuana 
users supported marijuana legalisation. 
Multivariable models showed that lower 
marijuana harm perceptions and lifetime 
and past 30-day tobacco use were 
common predictors of support for marijuana 
legalisation and intentions to use marijuana 
among non-users of marijuana. State-level 
marijuana policy was not associated with 
the level of agreement for marijuana 
legalisation. 
Davis et al. 
(2016) 
Colorado and 
Washington 
September 2014 
None Self-reported 
driving while 
intoxicated or 
within 1 hour 
of consuming 
marijuana 
Demographic 
variables 
Point in time Online survey of past-month 
users (n = 865; 399 from 
Colorado, 446 from 
Washington); 
logistic regression 
Prevalence of past-year driving while under 
the influence of marijuana was 43.6 % 
among respondents. The prevalence of 
driving within 1 hour of using marijuana at 
least five times in the past month was 
23.9 %. Increased perception that driving 
high is unsafe was associated with lower 
odds of past-year marijuana DUIs 
(OR = 0.31, p < 0.01) and lower past-month 
odds of driving five or more times within 1 
hour of using marijuana (OR = 0.26, 
p < 0.01). 
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Control measures Outcome Independent 
variable(s) 
REC-specific 
policy change 
Data and methods Findings 
Dilley et al. 
(2017) 
Washington 
June 2016 
None Local-level 
regulations 
and public 
opinion 
REC Point in time Descriptive assessment of 
marijuana-related municipal 
and county ordinances 
(n = 181)  
A total of 125 cities and 30 counties had 
passed local ordinances to address 
recreational marijuana retail sales. Multiple 
communities implemented retail market 
bans, including some temporary bans 
(moratoria), while considering whether or 
not to pursue other policy options. As of 30 
June 2016, 30 % of the state population 
lived in places that had temporarily or 
permanently banned retail sales. 
Communities frequently enacted zoning 
policies that explicitly regulated where 
marijuana businesses could be established. 
Other policies included in ordinances 
placed limits on business hours and 
distance requirements (buffers) between 
marijuana businesses and youth-related 
land use types or other sensitive areas. 
Dilley et al. 
(2019) 
Washington 
2010-12 and 
2014-16 
Pre/post REC Past month 
prevalence 
  Washington Healthy Youth 
Survey of 8th, 10th, and 
12th graders 
HYS shows statistically significant declines 
in prevalence from 2010-2012 to 2014-
2016 among both 8th graders (from 9.8 % 
[95 % CI, 9.1 %-10.5 %] to 7.3 % [95 % CI, 
6.6 %-8.0 %]; P < .001) and 10th graders 
(from 19.8 % [95 % CI, 18.6 %-21.0 %] to 
17.8 % [95 % CI, 16.7 %-18.9 %]; P = .01). 
Estoup et al. 
(2016) 
Washington 
2010-15 
Pre-REC cohort Perceived risk 
and frequency 
of use of 
marijuana in 
adolescents 
REC No date or year 
specified 
Self-referred students with 
problematic drug use, 
enrolled in school-base 
substance use intervention 
(n = 262; 144 pre-
legalisation); mediation 
model with non-parametric 
hypothesis testing 
Findings indicated a significantly positive 
correlation between marijuana-related 
consequences and perceived risk post 
legalisation. Despite relatively equal use in 
both groups, adolescents in the legalisation 
group experienced higher levels of 
perceived risk and increased negative 
consequences. 
Everson et al. 
(2019) 
Washington 
2009-16 
None. Proximity to 
dispensary 
Past month 
prevalence 
REC REC enactment 
and proximity to 
nearest retail 
outlet to 
respondent ZIP 
code 
Washington Behavioral Risk 
Factor Surveillance System 
(BRFSS) 
Current use increased among adults living 
in areas within 18 miles of a retailer and, 
especially, within 0.8 miles (odds ratio 
[OR] = 1.45; 95 % confidence interval 
[CI] = 1.24, 1.69). Frequent use increased 
among adults living within 0.8 miles of a 
retailer (OR = 1.43; 95 % CI = 1.15, 1.77). 
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Control measures Outcome Independent 
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REC-specific 
policy change 
Data and methods Findings 
Fiala et al. 
(2017) 
Oregon 
November 2015 
and April-May 
2016 
Pre/post Viewing 
marijuana 
promotion 
Demographic 
variable and 
county of 
residence 
None  Repeated cross-sectional 
online survey (n = 4 001) of 
adults (18+ years); non-
parametric hypothesis 
testing (chi-squared test). 
More than half of adults (54.8 %) state-wide 
reported seeing marijuana advertising in 
the past month. These adults reported that 
they most frequently saw store-front 
(74.5 %), street-side (66.5 %) and billboard 
(55.8 %) advertising. Exposure did not 
significantly differ by participant’s age or 
marijuana use but was higher among those 
living in counties with retail sales (56.5 %) 
than among those living in counties without 
(32.5 %). 
Freisthler et 
al. (2017) 
Denver census 
tracts 
January 2013-
October 2015 
None Violent, 
property and 
marijuana-
specific crime 
(crimes that 
involved 
marijuana and 
licensed 
facilities) 
REC MED/REC 
dispensary 
density over 
time 
Denver Police data of 481 
census blocs over 34 
months (n = 16 354); 
Bayesian Poisson space-
time model 
Independent of the effects of covariates, 
densities of marijuana outlets were 
unrelated to property and violent crimes in 
local areas. However, the density of 
marijuana outlets in spatially adjacent 
areas was positively related to property 
crime in spatially adjacent areas over time. 
Furthermore, the density of marijuana 
outlets in local and spatially adjacent block 
groups was related to higher rates of 
marijuana-specific crime. This study 
suggests that the effects of the availability 
of marijuana outlets on crime do not 
necessarily materialise within the specific 
areas where these outlets are located but 
may materialise in adjacent areas. 
Grant et al. 
(2017) 
Washington 
February 2001 to 
July 2015 
Pre-REC cohort Self-reported 
past-month 
use of 
marijuana in 
pregnant 
women 
REC Pre REC to REC 
enactment and 
implementation  
Women enrolled in the 
Parent-Child Assistance 
Program (n = 1 359; pre 
REC = 997, post 
REC = 362); non-parametric 
hypothesis testing (chi-
squared test) 
Women who completed the intervention 
after marijuana legalisation were 
significantly more likely (OR = 2.1, 
p < 0.0001) to report marijuana use on 
exiting the programme than women who 
completed the intervention before 
marijuana legalisation. Across both cohorts 
(pre and post legalisation), the authors 
found a positive link between marijuana 
use on exit and alcohol, illegal methadone, 
other opioids, amphetamines and cocaine 
use. 
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REC-specific 
policy change 
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Hall, K. E. et 
al. (2018) 
Colorado 
2012-14 
Pre/post ED episodes REC Pre-REC to REC 
implementation 
Colorado Hospital 
Association data  
State-wide data demonstrated a fivefold 
rise in the prevalence of mental health 
diagnoses among cannabis-associated ED 
visits (prevalence rate = 5.35, 95 % CI 5.27 
to 5.43), compared with ED visits not 
related to cannabis. The hospital 
subpopulation supported this finding with a 
fourfold rise in the prevalence of psychiatric 
complaints among ED visits attributable to 
cannabis (prevalence rate = 4.87, 95 % 
CI  4.36 to 5.44), compared with ED visits 
that were not attributable to cannabis. 
State-wide rates of ED visits associated 
with both cannabis and mental health 
significantly increased from 224.5 per 
100 000 in 2012 to 268.4 per 100 000 in 
2014 (p < 0.0001). 
Hunt and 
Pacula (2017) 
Colorado and 
Washington 
October 2013, 
May 2014, 
October 2014 
Pre-REC cohort Reported retail 
price 
REC/MED REC enactment 
to REC 
implementation 
Longitudinal survey of three 
waves (RAND Marijuana 
Use in West Coast States 
Survey) (n = 317 past-month 
users); 
Weedmap data on price 
(n = 3 802); difference-in-
difference approach 
Results indicate that there were no impacts 
on the prices paid for medical or 
recreational marijuana by state 
representative residents within the short 4- 
to 5-month window following legalisation. 
However, there were differences in how 
much people paid for marijuana for 
recreational purposes from a recreational 
store. 
Jones et al. 
(2018) 
Colorado 
October 2013 to 
March 2015 
US (whether REC 
was in place or not) 
Frequency of 
marijuana use 
in college 
students 
REC REC enactment 
to REC 
implementation 
 
Repeated cross-sectional 
surveys (n = 1 413; pre 
REC = 424; post 
REC = 989), compared with 
responses from National 
College Health Assessment 
for 2015; parametric 
hypothesis testing, ANOVA 
The prevalence of marijuana use in 
Colorado college students is much higher 
than the national average (71 % v 39 %, 
respectively; p < 0.001), especially the 
percentage of daily or almost daily users 
(25 % v 2 %, respectively; p < 0.001). 
There were significant differences found 
between non-users of marijuana and the 
marijuana users that use once a week or 
more but not daily in regard to the grade 
point average (F(6,227) = 2.935, p < 0.001). 
In addition, it seems that the relationship 
between alcohol and marijuana use in 
general has decreased since Amendment 
64 was passed but not among binge 
drinkers. 
Kerr, D. et al. 
(2017) 
Students in one 
large public 
university in 
Oregon 
2012-16 
Students from six 
universities in non-
REC states 
Changes in 
marijuana, 
alcohol and 
cigarette use 
in college 
students 
REC Pre REC to REC 
enactment and 
implementation 
in July 2015 
Repeated cross-sectional 
survey (n = 10 924) of 
undergraduates; mixed-
effects logistic regression 
Rates of Oregon college students’ 
marijuana use increased (relative to that of 
students in other states) following 
recreational marijuana legislation in 2015 
but only for those who reported recent 
heavy use of alcohol. 
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Kerr, D. et al. 
(2018) 
University 
students in 
Oregon 
2008-16 
Students from 123 
other universities in 
non-REC states 
Changes in 
cannabis use 
prevalence 
REC REC 
implementation 
Repeated cross-sectional 
survey in Oregon (n = 7 412) 
and 123 institutions (n = 
274 340) 
Following REC, Oregon students 
(compared to non-REC-state students) 
showed relative increases in rates of 
marijuana use (odds ratio [OR] = 1.29, 
95 % confidence interval [CI: 1.13, 1.48], 
p = .0002, and decreases in tobacco use 
rates (OR = .71, 95 % CI [.60, .85], 
p < .0001). 
Kerr, W. C. et 
al. (2018) 
Washington 
2012, 2014-15 
None Self-reported 
past-year use 
in survey year 
and in 2012 in 
adults 
REC Pre REC to REC 
enactment and 
implementation 
Cross-sectional 
representative phone 
surveys (n = 3 451); 
multinomial logistic 
regression 
A small increase of 1.2 percentage points 
in past-year use prevalence, from 24.3 % 
(22.3-26.5 %) to 25.6 % (23.6-27.6 %), 
which is not statistically significant, was 
found when combining the surveys. No 
statistically significant change was found in 
the prevalence of the simultaneous use of 
cannabis and alcohol — it decreased from 
12.9 % (11.3-14.7 %) to 12.6 % (11.0-
14.4 %). 
Kerr, W. C. et 
al. (2017) 
Respondents in 
states with 
REC/MED policy 
1984-2015 
Respondents in 
states without 
REC/MED policy  
Past-year 
marijuana use 
MED, REC, 
provision for 
dispensary, 
home 
cultivation 
REC adoption Repeated cross-sectional 
quinquennial National 
Alcohol Survey of adults 
(18+) (n = 37 359); 
fixed-effects approach for 
age-period-cohort effects 
Period effects were the main driver of rising 
marijuana use prevalence. Models 
including indicators of medical and 
recreational marijuana policies did not find 
any significant positive impacts. 
Kim and 
Monte (2016) 
Colorado 
2001-14 
Pre/post ED episodes 
for cannabis 
MED 
REC 
Pre REC to 
MED/REC 
enactment and 
implementation 
Retrospective data from the 
Colorado Hospital 
Association, a consortium of 
more than 100 hospitals in 
the state; parametric 
hypothesis testing 
The prevalence of hospitalisations for 
marijuana exposure in patients aged 9 
years and more than doubled after the 
legalisation of medical marijuana (from 15 
per 100 000 hospitalisations during the 
period 2001-09 to 28 per 100 000 
hospitalisations during the period 2010-13; 
p < 0.001), and ED visits nearly doubled 
after the legalisation of recreational 
marijuana (from 22 per 100 000 ED visits 
during the period 2010-13 to 38 per 
100 000 ED visits during January to June 
2014; p < 0.001). 
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Kim et al. 
(2016) 
Colorado 
2011-14  
Pre/post ED episodes 
for cannabis 
REC Pre REC to 
MED/REC 
enactment and 
implementation 
Retrospective data from 
Colorado Hospital 
Association  
The data from the Colorado Hospital 
Association did not show a significant 
change from 2011 to 2012 in the rate of ED 
visits with ICD-9 codes of cannabis use 
among out-of-state residents; however, 
from 2012 to 2014, the state-wide rate 
among out-of-state residents rose from 78 
per 10 000 visits in 2012 to 112 per 10 000 
visits in 2013 and 163 per 10 000 visits in 
2014 (rate ratios, 1.44 (2012-13) and 1.46 
(2013-14); p < 0.001 for both comparisons). 
Among Colorado residents, from 2011 to 
2014, the rate of ED visits possibly related 
to cannabis use increased from 61 to 70, 
86 and 101, respectively, per 10 000 visits 
(rate ratios, 1.14 (2011-12), 1.24 (2012-13) 
and 1.17 (2013-14); p < 0.001 for all 
comparisons). 
Lane and Hall 
(2019) 
Colorado, 
Washington and 
Oregon 
2009-16 
Kansas, Nebraska, 
New Mexico, 
Oklahoma and Utah 
(Colorado 
neighbours); British 
Columbia and 
Oregon (Washington 
neighbours); and 
California and 
Nevada (Oregon 
neighbours) 
Monthly motor 
vehicle 
fatalities  
REC REC 
implementation 
in each state 
Interrupted time series using 
CDC WONDER data on 
vehicle fatalities 
There was a pooled step increase of 1.08 
traffic fatalities per million residents 
followed by a trend reduction of −0.06 per 
month (both P < 0.001). The results 
suggest that legalizing the sale of cannabis 
for recreational use can lead to a temporary 
increase in traffic fatalities in legalizing 
states that can spill over into neighbouring 
jurisdictions. 
Livingston et 
al. (2017) 
Colorado 
2000-15 
Pre/post Monthly 
opioid-related 
fatalities 
REC REC 
implementation 
January 2014 
Interrupted time series Colorado’s legalisation of recreational 
cannabis sales and use resulted in a 0.7 
deaths-per-month (b = −0.68; 95 % CI = 
−1.34 to −0.03) reduction in opioid-related 
deaths. This reduction represents a 
reversal of the upwards trend in opioid-
related deaths in Colorado. 
Makin et al. 
(2018) 
Colorado and 
Washington 
2010-15 
The rest of the US 
as one unit 
Violent and 
property crime 
clearance 
rates 
REC Pre REC to REC 
enactment 
Monthly counts of crime 
from FBI Uniform Crime 
Reporting data; interrupted 
time-series analysis 
Findings suggest there are no negative 
effects of legalisation on crime clearance 
rates. Moreover, evidence suggests that 
some crime clearance rates have 
improved. Our findings suggest legalisation 
has resulted in improvements in some 
clearance rates. 
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Mason et al. 
(2016) 
Washington 
2010/11 to 
2013/14 
Pre-REC cohort Self-reported 
past-month 
use in 
adolescents 
Second survey 
wave (just 
prior to REC) 
Pre REC to REC 
enactment 
 
Two wave cohort study of 
8th/9th graders from 
Tacoma, Washington 
(n = 238); multivariate, 
multilevel modelling 
Marijuana use was higher for the second 
cohort than for the first cohort, but this 
difference was not statistically significant. 
Rates of cigarette and alcohol use were 
slightly lower in the second cohort than in 
the first cohort. 
McGinty et al. 
(2017) 
Respondents in 
states that passed 
REC 
April 2016 
Respondents in 
states that did not 
pass REC 
Public opinion 
and 
arguments 
for/against 
legalisation 
REC Point in time Nationally representative 
sample of US adults 
(n = 979; 334 from Colorado, 
Washington, Arkansas, 
Oregon, DC); 
ordered logit and non-
parametric hypothesis 
testing (chi square) 
Respondents rated pro-legalisation 
arguments highlighting beneficial economic 
and criminal justice consequences as more 
persuasive than anti-legalisation 
arguments, emphasising adverse public 
health effects. Respondents were more 
likely to agree with arguments highlighting 
legalisation’s potential to increase tax 
revenue (63.9 %) and reduce prison 
overcrowding (62.8 %) than arguments 
emphasising the negative consequences of 
motor vehicle crashes (51.8 %) and youth 
health (49.6 %). The highest rated anti-
legalisation arguments highlighted the 
conflict between state and federal 
marijuana laws (63.0 %) and asserted that 
legalisation will fail to eliminate the illicit 
market (57.2 %). Respondents who 
endorsed pro-legalisation economic and 
criminal justice arguments were more likely 
than other respondents to support 
legalisation. Respondents living in 
Arkansas, Colorado, DC, Oregon and 
Washington were significantly (p < 0.05) 
more likely to agree with 11 of the 13 pro-
legalisation arguments and significantly 
less likely to agree with 10 of the 13 anti-
legalisation arguments than respondents 
living in non-legalisation states. 
Miller et al. 
(2017) 
Washington 
2005-15 
Pre-REC cohort Past-month 
marijuana use 
in college 
students 
REC Pre REC to REC 
enactment and 
implementation 
Repeated cross-sectional 
surveys of undergraduates 
at Washington State 
University who participated 
in the National College 
Health Assessment 
(n = 13 335); logit and OLS 
regression 
Students at Washington State University 
experienced a significant increase in 
marijuana use after legalisation. This 
increase is larger than the increase that 
would be predicted by national trends. The 
change is strongest among females, Black 
students and Hispanic students. The 
increase for underage students is as much 
as that for legal-age students. We find no 
corresponding changes in the consumption 
of tobacco, alcohol or other drugs. 
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Pacula et al. 
(2016) 
Colorado and 
Washington 
October 2013 
Oregon and New 
Mexico 
Prevalence 
rates and use 
behaviours 
between MED 
and REC 
users 
REC Point-in-time 
measure during 
REC enactment 
Cross-sectional sample of 
representative phone survey 
(n = 1 994; 
Washington = 787, 
Oregon = 506; 
Colorado = 503; New 
Mexico = 213) 
Recreational use is considerably higher 
than medical use across all states (41 %), 
but it is the highest in Oregon and 
Washington. Approximately 86 % of people 
who report ever using cannabis for 
medicinal purposes also use it 
recreationally. Fewer than one in five 
recreational users report simultaneous use 
of alcohol and cannabis most or all of the 
time, and fewer than 3 % of medicinal 
users report frequent simultaneous use of 
alcohol and cannabis. In the US, the 
degree of overlap between medicinal and 
recreational cannabis users is 86 %. 
Medicinal and recreational cannabis users 
favour different modes and amounts of 
consumption. 
Parnes et al. 
(2018) 
Colorado 
Spring 2013 to 
autumn 2015 
Pre-REC cohort Self-reported 
cannabis use 
in college 
students 
REC REC enactment 
to 
implementation 
Undergraduate survey 
(n = 5 241); non-parametric 
hypothesis test (chi-squared 
test) 
Cannabis use has increased for all 
students since recreational legalisation, but 
more so for those over 21 years. No 
differences in past-month use frequency 
were found between pre- and post-
legalisation. The influence of cannabis laws 
on non-resident students’ decision to attend 
a Colorado college predicted lifetime and 
past 30-day use. In addition, out-of-state 
students reported higher past 30-day use 
than in-state students. 
Rusby et al. 
(2018) 
Oregon 
Spring 2014 and 
2015 
Pre-REC cohort Self-reported 
cannabis use 
in adolescents 
REC REC enactment 
to 
implementation 
Two cohorts of 8th/9th 
graders (n = 444); 
multivariate linear regression 
In communities opting out of sales, the 
prior-to-legalisation cohort was less likely to 
increase their willingness and intent to use 
marijuana, and the legalisation cohort was 
more likely to increase their intent to use. 
For young people who used marijuana, 
legalisation was associated with increased 
use, and those in communities opting out of 
sales experienced a larger growth in 
marijuana use. Community policy appears 
to impact young people’s attitudes towards 
and use of marijuana. The results suggest 
that the legalisation of recreational 
marijuana did not increase marijuana use 
among young people who did not use 
marijuana, but it did increase use among 
young people who were already using. 
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Smart et al. 
(2017) 
Washington 
July 2014-
September 2016 
None Changes in 
price, potency 
and product 
REC Post REC 
implementation 
only 
Transaction sale data from 
regulators 
Traditional cannabis flowers still account for 
the majority of spending (66.6 %), but the 
market share of extracts for inhalation 
increased by 145.8 % between October 
2014 and September 2016, now comprising 
21.2 % of sales. The average THC-level for 
cannabis extracts is more than triple that 
for cannabis flowers (68.7 % compared to 
20.6 %). For flower products, there is a 
statistically significant relationship between 
price per gram and both THC [coefficient = 
0.012; 95 % confidence interval (CI) = 
0.011–0.013] and CBD (coefficient = 0.017; 
CI = 0.015–0.019). 
The estimated discount elasticity is +0.06 
(CI = +0.07 to +0.05). Traditional cannabis 
flowers still account for the majority of 
spending (66.6 %), but the market share of 
extracts for inhalation increased by 
145.8 % between October 2014 and 
September 2016, now accounting for 
21.2 % of sales. The average THC level for 
cannabis extracts is more than triple that 
for cannabis flowers (68.7 % compared 
with 20.6 %). For flower products, there is a 
statistically significant relationship between 
price per gram and both THC 
(coefficient = 0.012; 95 % CI  0.011 to 
0.013) and CBD (coefficient = 0.017; 95 % 
CI 0.015 to 0.019). The estimated discount 
elasticity is –0.06 (95 % CI –0.07 to –0.05). 
Subbaraman 
and Kerr 
(2016) 
Washington 
January-October 
2014 
Pre/post Support for 
legalisation 
Demographic 
variable 
Post REC 
implementation 
Random digit dialling of 
residents (n = 2007); 
bivariate tests and 
multivariate regressions 
Less than 5 % of those who voted for 
marijuana legalisation would change their 
vote, whereas 14 % of those who voted 
against legalisation would change their 
vote. In multivariable models controlling for 
demographics, substance use and 
marijuana-related opinions, those who 
voted for legalisation had half the odds of 
changing their vote than those who voted 
against it. Among past-year non-marijuana 
users, almost 10 % were somewhat/very 
likely to use marijuana if they could buy it 
from a legal store. 
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Reference Location and 
years evaluated 
Control measures Outcome Independent 
variable(s) 
REC-specific 
policy change 
Data and methods Findings 
Sokoya et al. 
(2018) 
Denver, Colorado 
2012-15 
Pre/post ED visits REC Pre REC to 
MED/REC 
enactment and 
implementation 
Hospital data from the 
University of Colorado 
Hospital and Denver Health 
Medical Centre; 
non-parametric hypothesis 
test 
Maxillary and skull base fracture 
proportions significantly increased following 
legalisation (p < 0.001 and p < 0.001, 
respectively). No significant differences 
were seen in the proportion of patients who 
lived in urban and rural counties before and 
after legalisation (p > 0.05). 
Wang et al. 
(2016) 
Colorado 
2009-15 
Pre/post Paediatric 
exposures to 
marijuana 
MED 
REC 
Pre REC to 
MED/REC 
enactment and 
implementation 
Retrospective cohort study 
of hospital child admissions 
at Children’s Hospital 
Colorado and cannabis 
exposure incidents reported 
to poison control; 
Poisson regression 
The mean rate of marijuana-related visits to 
the children’s hospital increased from 1.2 
per 100 000 population 2 years prior to 
legalisation to 2.3 per 100 000 population 2 
years after legalisation (p = 0.02). Annual 
poison control paediatric marijuana cases 
increased more than fivefold from 2009 (9) 
to 2015 (47). Colorado had an average 
increase in poison control cases of 34 % 
(p < 0 .001) per year, while the remainder 
of the US had an increase of 19 % 
p <  0.001). 
Wang et al. 
(2017) 
Colorado 
2000-15 
Pre/post Annual rates 
of 
hospitalisation
s, ED events 
and poison 
control calls 
for marijuana 
MED 
REC 
Pre REC to 
MED/REC 
enactment and 
implementation 
Univariate Poisson 
regression 
From 2000 to 2015, hospitalisation rates 
with marijuana-related billing codes 
increased from 274 per 100 000 
hospitalisations to 593. Overall, the 
prevalence of mental illness among ED 
visits with marijuana-related codes was five 
times higher (5.07, 95 % CI 5.0 to 5.1) than 
the prevalence of mental illness among ED 
visits without marijuana-related codes. 
Poison control calls remained constant 
from 2000 to 2009. However, in 2010, after 
local medical marijuana policy 
liberalisation, the number of marijuana 
exposure calls significantly increased, from 
42 to 93; in 2014, after recreational 
legalisation, calls significantly increased by 
79.7 %, from 123 to 221 (p < 0.0001). 
Wang et al. 
(2018) 
Colorado 
2005-15 
Pre/post Children ED 
visits for 
cannabis 
REC 
MED 
Pre REC to 
MED/REC 
enactment and 
implementation 
Retrospective review of 
annual number of marijuana-
related visits to ED 
(n = 4 202) 
Marijuana-related visits increased from 1.8 
per 1 000 visits in 2009 to 4.9 in 2015 
(p = <  0.0001). 
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Reference Location and 
years evaluated 
Control measures Outcome Independent 
variable(s) 
REC-specific 
policy change 
Data and methods Findings 
Wen and 
Hockenberry 
(2018) 
Alaska, Colorado, 
Oregon and 
Washington 
Q1 2011 to Q2 
2016 
Non-REC states State-level 
opioid 
prescribing 
rates covered 
by Medicaid 
MED 
REC 
REC 
implementation 
State drug utilisation data 
from the Centres for 
Medicare and Medicaid 
Services;  
difference-in-difference 
approach, two-way fixed 
effects 
The state implementation of medical 
marijuana laws was associated with a 
5.88 % lower rate of opioid prescribing 
(95 % CI −11.55 % to approximately 
−0.21 %). Moreover, the implementation of 
adult-use marijuana laws, which all 
occurred in states with existing medical 
marijuana laws, was associated with a 
6.38 % lower rate of opioid prescribing 
(95 % CI −12.20 % to approximately 
−0.56 %). 
Shi et al. 
(2016) 
Census tracts in 
Colorado 
2015 
 REC and MED 
store density 
MED 
REC 
 Cross-sectional ecological 
study of all census tracts in 
the state (n = 1 249); 
parametric hypothesis 
testing  
Regardless of store type, marijuana stores 
were more likely to be located in 
neighbourhoods that had a lower proportion 
of young people, a larger racial and ethnic 
minority population, a lower household 
income, a higher crime rate or a greater 
density of on-premise alcohol outlets. The 
availability of medical and recreational 
marijuana stores was differentially 
correlated with household income and 
racial and ethnic composition. 
Working papers 
Hansen et al. 
(2017b) 
Washington 
2015 
Pre/post Inter-state 
trafficking after 
REC 
implementatio
n in Oregon 
REC (opening 
of retail stores 
in Oregon) 
REC 
implementation 
in Oregon 
Washington retail 
transaction data; 
regression discontinuity 
design 
Washington retailers situated along the 
Oregon border experienced a 41 % decline 
in sales immediately following Oregon’s 
cannabis market opening. In counties that 
are the closest crossing point for the 
majority of the neighbouring population, the 
estimated decline in sales has grown to 
58 % and is the largest for the biggest 
transactions. 
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Reference Location and 
years evaluated 
Control measures Outcome Independent 
variable(s) 
REC-specific 
policy change 
Data and methods Findings 
Hansen et al. 
(2018) 
Washington and 
Colorado 
2000-16 
Non-REC states in 
the US 
Motor vehicle 
crash fatality 
REC REC 
implementation 
in 2014 
Annual number of motor 
vehicle fatalities reported in 
the Fatality Analysis 
Reporting System; synthetic 
control approach 
Between 2013 and 2016, the number of 
drivers who tested positive for THC 
increased in Colorado and Washington, by 
92 % and 28 % respectively. However, 
identifying a causal effect is difficult 
because of the presence of significant 
confounding factors. Hansen et al. found 
that ‘the synthetic control groups saw 
similar changes in marijuana-related, 
alcohol-related and overall traffic fatality 
rates despite not legalising recreational 
marijuana’. 
Hao and 
Cowan (2017) 
Counties in 
Washington and 
Colorado 
2009-14 
Counties in 
neighbouring states 
just over the border 
Arrests and 
self-reported 
marijuana use 
REC Pre REC to REC 
enactment 
FBI Uniform Crime 
Reporting Data at county 
level; NSDUH state-level 
prevalence data; difference-
in-difference approach, 
synthetic controls for 
robustness check 
There is no conclusive evidence that 
marijuana sale/manufacture arrests, DUI 
arrests or opium/cocaine possession 
arrests in border states are affected by 
REC. The NSDUH data show that self-
reported marijuana use in states that 
border REC states increased after REC, 
compared with those states that do not 
share borders with REC states. 
Highway Loss 
Data Institute 
(2017) 
Colorado, 
Washington and 
Oregon 
January 2012 to 
October 2016 
Neighbouring states: 
Nebraska, Utah, 
Wyoming, Montana, 
Idaho and Nevada 
Auto 
insurance 
collision claim 
rates 
REC REC 
implementation  
Monthly insurance collision 
claims; Poisson regression 
and non-parametric 
hypothesis testing 
Results from single-state analyses as well 
as the combination of the three states 
indicate that collision claim frequencies 
increased significantly when retail sales 
commenced. When states are examined 
individually, the frequency of collision 
claims increases by between 4.5 % and 
13.9 %. A single analysis that combined the 
three states with legal recreational use 
found a smaller yet significant increase of 
2.7 %. 
REC, recreational marijuana law; MED, medical marijuana law; SD, standard deviation; ANOVA, analysis of variance; OLS, ordinary least squares. 
REC adoption: when an initiative was passed by voters but was not in effect. 
REC enactment: when laws were put into place to effect a legal change. 
REC implementation: when the laws were fully operational and stores were open. Note: advocate-produced reports are not included.  
TECHNICAL REPORT I Monitoring and evaluating changes in cannabis policies: insights from the Americas  
 
69 
 
Appendix C: Additional trend data 
Prevalence 
In the figures below, we plot prevalence rates reported by the NSDUH for various age cohorts and states. 
To help the reader, we also include a reference table of legal MED/REC dates of adoption and 
implementation, the latter referring to when qualified patients or adults were able to access and use 
cannabis. Keep in mind that many early MED states did not have any dispensaries or commercial store 
fronts for several years after adopting or implementing MED. 
TABLE AC1 
Dates of MED/REC adoption and implementation 
 Medical cannabis  Recreational cannabis 
State Adoption Year that stores 
legally opened 
 Adoption Implementation 
Alaska November 1998 NA  November 2014 October 2016 
Colorado November 2000 2005  November 2012 January 2014 
District of Columbia November 1998 2010  November 2014 February 2015 
Oregon November 1998 2009  November 2014 October 2015 
Washington November 1998 NA  November 2012 July 2014 
 
The series of charts below plot the past-month prevalence rate of use of cannabis among the general 
population (aged 12 and over) in Alaska, Colorado, DC, Oregon, Washington and the US as a whole 
between 2003 and 2017. State estimates were taken from the NSDUH’s 2-year pooled estimates, 
assigning the latter year for each of the year (e.g. pooled estimates for 2016 to 2017 represent 2017). To 
show the change in prevalence rates relative to policy changes, we have plotted vertical dashed/dotted 
lines to indicate the year in which MED dispensaries opened (a dotted line, where applicable), when REC 
was adopted (i.e. voted into law; this is represented by a light-grey dashed line) and when REC was 
implemented (i.e. when stores started opening; this is represented by a dark-grey dashed line). Because 
we are using annual data, these vertical lines roughly approximate the timing of a policy change. For 
example, voters of a state may have adopted REC in November 2014, even though the year was nearly 
over after the law passed. 
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FIGURE AC1 
Past-month cannabis use prevalence (%) in Alaska among those aged 12 years and older  
 
Source: NSDUH 
FIGURE AC2 
Past-month cannabis use prevalence (%) in Colorado among those aged 12 years and older  
 
Source: NSDUH 
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FIGURE AC3 
Past-month cannabis use prevalence (%) in DC among those aged 12 years and older  
 
Source: NSDUH 
FIGURE AC4 
Past-month cannabis use prevalence (%) in Oregon among those aged 12 years and older  
 
Source: NSDUH 
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FIGURE AC5 
Past-month cannabis use prevalence (%) in Washington state among those aged 12 years and 
older  
 
Source: NSDUH 
Data from the MTF survey show little change in past-month cannabis use among 8th, 10th and 12th 
graders (pooled) between 2009 and 2017. In 2009, 13.8 % of respondents reported using cannabis at 
least once in the past month. This rate peaked in 2013, at 15.6 %, declining to 14.5 % in 2017. However, 
past-month use rates have steadily increased among college students. In 2009, 18.5 % of respondents 
reported using cannabis at least once in the past month. By 2016, the rate had climbed to 22.2 %. 
Data from biennial state surveys add additional information to the changes in prevalence rates among 
high school students post REC. These state surveys randomly sample students from selected middle 
schools and high schools. The HKCS sampled about 17 000 students from 157 schools across the state 
in 2015. The Washington state’s HYS surveyed over 230 000 students in over 1 000 schools in 2016. In 
Table AC2 we report available prevalence estimates for high school students and adults reported in state 
surveys in recent years, along with estimates from the Behaviour Risk Factor Surveillance System 
(BRFSS) of the Centers for Disease Control and Prevention. However, past-month prevalence rates 
among high school students or 12th graders have remained flat or declined in both states.  
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TABLE AC2 
Surveys and reported past-month cannabis prevalence rates for Colorado and Washington 
Survey 2009/10 2011/12 2013/14 2015/16 
Colorado, past-month (18+) BRFSS   13.6 13.5 
Colorado, daily/near-daily (18+) BRFSS   6 6.35 
Colorado, past-month (high school) HKCS* 25 22 20 21 
Washington, past-month (12th grade) HYS 26 27 27 26 
Washington, heavy past-month (12th grade) HYS**  9 10 11 
*Estimates are for odd years; otherwise they are even. 
**Heavy use is defined as using on 10+ days in the last 30. 
Hospital and poison control centres 
Data from hospitals and poison control centres allow researchers to gauge the initial public health 
incidents associated with post-REC implementation. Below we plot the rate of ED events and 
hospitalisations involving cannabis. ED episodes have increased since 2011 but not as rapidly as 
hospitalisations. Rates remained relatively flat until 2013, when they started to rise just prior to REC 
enactment. Data for 2015 are an estimated annual rate, as only counts from January to September are 
publicly available. We were unable to find ED or hospitalisation data from Washington state. 
FIGURE AC6 
Adverse events involving cannabis per 100 000 population in Colorado 
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The figure below shows the reported calls to poison control centres involving cannabis per 100 000 
residents for both Washington and Colorado. In Colorado since 2011, calls involving cannabis between 
2011 and 2014, when they levelled off in 2014 at about 4 per 100 000. Washington saw a similar 
increase, with rates rising in 2014, then levelling off for 2 years before rising again in 2016/17 to similar 
per capita rates as in Colorado. 
FIGURE AC7 
Poison control calls per 100 000 population 
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Traffic fatalities 
The National Highway Traffic Safety Administration’s Fatality Analysis Reporting System (FARS) reports 
data on the number of traffic fatalities per 100 million vehicle miles travelled. The rate of traffic fatalities in 
most states analysed was fairly linear between 2009 and 2017 (the obvious exceptions are DC, which is 
mostly urban, and Alaska, which is mostly rural; both may suffer from extreme year-to-year variability). 
However, starting around 2013, Oregon, Colorado and Washington show a marked increase compared 
with the rest of the US. 
FIGURE AC8 
Traffic fatality rate per 100 million vehicle miles travelled  
 
Source: FARS 
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Arrests for cannabis possession and supply offences 
The figures below show rates of arrest for cannabis offences over time (where available). In all three 
states, arrest rates for cannabis offences have declined over the period. 
FIGURE AC9 
Cannabis possession arrests per 100 000 population 
 
FIGURE AC10 
Cannabis supply arrests per 100 000 population 
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